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V. ABSTRACT {FRENCH) 
La neurofibromatose 1 (NF 1) affecte un individu sur 3000 et se caractérise par 
l'extrême variabilité des symptôme cliniques. Le gène de NF/, situé sur le chromosome 
l 7q 11.2, contient 350 kb et 60 exons. Le taux de mutation est de 1 x 
104/gamète/génération. Environ 50% des mutations sont d'origine familiale et 50% 
sporadique. Nous avons identifié et caractérisé une mutation qui cause l'exclusion des 
exons 11 et l 2a, six délétions et un polymorphisme HinclI et aussi déterminé le 
déséquilibre de liaison dans la population québécoise. 
Une mutation originale a été identifiée grâce au test de tronquation des protéines; 
elle serait la cause de l'exclusion d'exons. Le séquençage de la région génomique entre 
les introns 1 Oc et 12a a permis d'identifier le changement d'un G en A en position 
2056+ l dans le site d' épissage 5' de l 'exon 12a. Ceci engendre l'excision des deux exons 
l l et 12a sans changement du cadre de lecture et sans que la quantité des ARN messagers 
en soit affectée. Des essais d'épissage in vivo et in vitro nous ont permis de démontrer 
pour la première fois que le mutation naturelle supprime la définition des exons. Nos 
résultats montrent aussi que la séquence encodée par les exons 11 et l 2a est essentielle 
pour l'activité de la neurofibromine. 
L 'haplotypage de 19 familles a permis de détecter la perte d'hétérozygosité 
(LOH) grâce aux 4 microsatellites et aux RFLPs RsaI et EcoRI. Six délétions (2 
familles:76 l 0 et 74 73, et 4 patients: 178, 184, 236 et 23 7) ont été identifiées et 
caractérisées par la LOH et des buvardages de type Southern. La délétion dans la famille 
7610 est d'origine maternelle et seul restent les exons l-4b. La délétion dans la famille 
xiv 
7473 est aussi d'origine maternelle et les exons de là 5 sont délétés, la délétion s'arrêtant 
quelque part avant l' intron 26. Avec le patient 1 78 la délétion commence entre les exons 
23-2 et 27b pour se terminer après la région 3' de NFJ. La délétion dans le patient 184 
commence au 5' du gène et se termine entre les exons 27b-29. La délétion dans le patient 
236 commence entre les exons 14-18 et se termine après l'extrémité 3' de NFJ. Avec le 
patient 237, la délétion commence entre les exons 38-45 et se termine après la région 3' 
du gène. Ces délétions sont distribuées au hasard dans le gène NF 1. 
Un polymorphisme Hi ne//, situé en position 5' du gène NF 1 a été mis en 
évidence. Il a été détecté grâce à une sonde faite à partir des exons 1 à 4a (nucléotides 2 à 
401 du cDNA). Trois alleles ont été détectées: Al (3.1 et 3.3 kb), A2 (2.4 et 4.0 kb), A3 
(1.3 et 5.1 kb). Les hétérozygotes sont Al-A2 et Al-A3. Les homozygotes sont Al-Al et 
A2-A2. Les fréquences des allèles Al, A2, A3 sont 0.545, 0.448 et 0.007 respectivement. 
Ce site est dans un intron. Nos résultats suggèrent aussi que la sonde révèle non pas un 
mais deux polymorphismes similaires. 
Les 4 microsatellites: IVS26-2.3, IVS27 AC28.4, IVS27 AC33. l et IVS38GT53.0 
sont fortement liés. Cependant on n'observe pas de déséquilibre de liaison et pas d'effet 
fondateur dans la population québécoise. 
Mes études ont identifié et caractérisé plusieurs mutations dans le gène NFJ. Ces 
études montrent que l'analyse des mutations est complexe. Je n'ai pas identifié de 
mutation spécifique ou fondatrice dans la population québécoise. 
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VI. ABSTRACT 
Neurofibromatosis type 1 (NF 1) aftlicts 1 in 3,000 individuals and is 
characterized with variable clinical presentations. The NF 1 gene spans 350 kb on 
chromosome l 7q 11.2 with 60 exons. The gene exhibits high mutation rate of l x 
104/gamete/generation and approximately 50% are sporadic new mutations. ln this study, 
a splice site mutation and 6 gross deletions have been identified and characterized. Also, 
a Hindi polymorphism was detected and the linkage disequilibrium was investigated. 
Using a protein truncation assay, we have identified a exon skipping mutation. 
The mutation, which consists of a G to A transition at position + 1 (2056+ 1) of the 5' 
splice site of exon 12a, is associated with the loss of both exons 11 and 12a in the NFl 
mRNA. This loss of two exons does not change the reading frame and yields normal 
amounts of mRNA. Through the use of in vivo and in vitro splicing assays, we show that 
the mutation inactivates the 5' splice site of exon 12a. ln addition, because this donor 
splice site is important to activate the upstream 3' splice site, the mutation prevents exon 
definition and leads to the skipping of both exons 11 and l 2a. These results document the 
first example of a natural mutation that inactivates exon definition, and suggest that the 
l l-12a region ofNFl plays an important role in the activity of neurofibromin. 
Six gross deletions (families 7610 and 7473, patients 178, 184, 236 and 236) have 
been identified and characterized by loss of heterozygosity analysis and Southern blot. 
The deletion in family 7610 arose from the maternai allele and all the NFJ gene except 
exons 1 to 4b, was deleted. The deletion in family 7473 was also derived from the 
maternai chromosome and exons 1-5 were deleted. The breakpoint of the deletion is 
xvi 
located between exons 5 and 26. ln the four non-family cases, for patient 178, the break 
point of the deletion was located between exons 23-2 and 27b and the region downstream 
of the breakpoint was deleted. For patient 184, the breakpoint of the deletion was 
between exons 27b and 29, and the region upstream of the breakpoint was deleted. With 
patient 236, the breakpoint of the deletion was between exons 14 and 18 and the gene 
downstream of the breakpoint was deleted. The breakpoint of the deletion of the patient 
237 was between exons 38 and 45 and the region upstream of the breakpoint was deleted. 
These six deletions were distributed randomly across NF 1 gene and no deletion hot spot 
was identified. The deletions are unique and different from those reported previously. 
The deletions are not associated with unusual clinical features. 
The Hincll polymorphism is located between exons 1 and 4a as defined by probe 
GE2-400 bp. Three alleles are detected: Al (3.1 and 3.3 kb), A2 (2.4 and 4.0 kb), A3 
(l.3 and 5.1 kb). The detected heterozygote forms are Al-A2, or Al-A3 and the 
homozygote forms Al-Al or A2-A2. The allele frequencies are 0.545, 0.448 and 0.007 
for Al, A2 and A3 respectively. The GE2-400 bp probe most probably detects the 
polymorphism in the NF J gene and at least in one other related locus. 
Analysis haplotypes of the 19 NFl families indicates that the four intragenic 
polymorphie microsatellites are strongly linked with the NF l disease. However, no 
linkage disequilibrium and founder effect was observed in this Québec population 
collection. 
In conclusion, the study shows that the anlysis of NF 1 gene mutation is complex. 
No particular founder mutation has been observed in the Québec population. 
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CHAPTER 1 INTRODUCTION 
The objective of this study is to identify and characterize mutations in the 
neurofibromatosis type l (NF l) gene. This thesis includes three major parts: the study of 
NF 1 mutations, the characterization of a splicing mutation and the analysis of linkage 
disequilibrium using the haplotype data. Therefore, the introduction covers three parts: 
neurofibromatosis type l (NFl) (section l.l), pre-mRNA splicing (section 1.2) and 
linkage disequilibrium (section 1.3). 
1.1 Neurofibromatosis type 1 (NFl) 
1.1.1 Clinicat features 
NFl is characterized by peripheral neurofibromas, café-au-lait spots, and Lisch 
nodules. Patients often exhibit additional less common complications including osseous 
lesions, optic glioma, learning disabilities and malignancy. NFl is known for its 
pleiotropic clinical manifestation and notable for its variable expressivity with clinical 
presentations that may vary from mild to severe even within the members of the same 
family (Rubsenstein and Korf, 1990; Riccardi, 1992; Carey and Viskochil, 1999). The 
diagnostic is according to the National Institutes of Health criteria for NFI (Table l) 
which are the most reliable means for the diagnosis (Feldkamp et al., 1998). 
l 
Table 1. Diagnostic Criteria for NFl 
The diagnostic criteria of the National Institutes of Health Consensus Conference on 
Neurofibromatosis (July, 1987) are met by an individual who demonstrates two or 
more of the following: 
• 6 or more café au lait macules of over 5 mm in diameter in prepubertal individuals 
and over 15 mm in diameter in postpubertal individuals 
• 2 or more neurofibromas of any type or one plexiform neurofibroma 
• axillary or inguinal freckling 
• optic glioma 
• 2 or more Lisch modules (iris hamartomas of melanotic origin) 
• a distinctive osseous lesion such as sphenoid dysphasia or thinning of the long bone 
cortex with or without pseudoarthrosis 
•a first-degree relative (parent, sibling, or offspring) with NFl by the above criteria 
2 
The inheritance pattern of NF 1 is autosomal dominant. NF 1 is considered 
completely penetrant. NFl bas an incidence of about 1 :3000 (Colman and Wallace, 1994; 
Friedman, 1999). 
1.1.2 The NF/ gene 
The NF/ gene spans approximately 350 kb of genomic DNA in chromosomal 
region 17ql 1.2. The NF 1 gene has 60 exons with intron sizes ranging from 
approximately 60 bp to more than 40 kb (Figure 1). It codes two transcripts of, 11 and 13 
kb, presumably due to different lengths of the 3' untranslated region. The NF/ cDNA has 
8454 bp. It encodes for a 2818 amino acid protein, neurofibromin which appears to 
associate with microtubules and is abundant in the endoplamic reticulum of neurons 
(Cawthon et al., 1990; Visochil et al., 1990; Wallace et al., 1990; Li et al., 1995; Colman 
and Wallace, 1994). Neurofibromin shows homology to various members of the GAP 
superfamily. These proteins include the mammalian GAP, the IRAI and IRA2 gene 
products of Saccharomyces cerevisiae, the sari gene product of Schizosaccharomyces 
pombe and Drosophila GAPl. The homology of the mammalian GAP and the 
Drosophila GAP l is restricted to the catalytic domain of 360 amino acids. There is more 
extensive homology of the yeast IRA l, IRA2, and sar 1 gene proteins (Xu et al., 1990; 
Buchberg et al., 1990; Hall, 1992). The homology of neurofibromin with C. e/egans has 
not been reported. Exons 2 l-27a specify a 360 amino acid domain which shows 
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F igure 1. T he NFJ gene. A. The proximate positions of exons related to introns. 
The exons are indicated as boxes while introns are indicated as horizontal lines. The 
GAP related domain (GRD) is as indicated. B. Schematic diagram representing the 
NF 1 exons which are represented as rectangular boxes and the size of each exon is as 
indicated in bp. Introns are not shown to scale. The transcription start is depicted as a 
horizontal arrow upstream of exon 1. Alternative exons are shaded. The NF 1 GAP 
related domain ( F l-GRD) and the three genes: EVI2A, EVI2B and OMGP , 
embedded in intron 27b are as indicated. These three genes are transcribed in the 
orientation opposite to the NF l gene. 
4 
(pl20-GAP) and the products of the yeast IRAI and IRA2 genes. This region is referred to 
as NFl GAP related domain (NFl-GRD) (Wallace et al., 1990; Li et al., 1995). 
Three small genes, EV/2A, EV/2B and OMGP, whose functions are not known, 
are embedded within intron 27b and transcribed in the opposite orientation of NF/ (Shen 
et al., 1996; Feldkamp et al., 1998; Viskochil, 1999). The search for homologous loci has 
shown NF/ related loci on chromosomes 2, 12, 14, 15, 18, 20, 21, 22 (Legius et al., 1992; 
Cummings et al., 1993; Gasparini et al., 1993). The locus on chromosome 12 contains 
open reading frames homologous to NF/ in at least two exons and is expressed in a 
number of tissues (Cummings et al., 1993). The complete sequence of the pseudogene on 
chromosome 22 consists of only the middle part of the NF l gene without exons 2 l-27a 
(Luijten et al., 2000). 
NF l gene has a complex expression profile. There are multiple sites of alternative 
splicing within the gene affecting exons 9a, 23a and 48a. The alternative transcripts 
exhibit developmental and tissue-specificity. Evidence suggests that RNA splicing and 
RNA metabolism play a critical role in the control of NF 1 gene expression. Seven 
distinct NF l mRNA isoforms (Table 2) have been detected (Skuse and Cappione, 1997) 
and four neurofibromin isoforms have been identified (Feldkamp et al., 1998). 
5 
Table 2. NF1 alternative transcripts 
Transcript name Alternative cxon includcd 
9br 
Type II 
Type III (rodent) 










Excludes exon 11 to most of 
exon 49 
Consequcncc in ncurofibromin 
Addition of l 0 amino acids 
Addition of 21 amino acids 
Introduction of frame shift 
Introduction of frame shift 
Addition of 21 amino acids 
Addition of 21 amino acids in 
GRD and 18 amino acids at 
carboxy terminus 
Excludes amino acids 548-2815 
6 
1.1.3 The NFJ fonctions 
It is believed that neurofibromin acts in the cellular signal transduction pathway 
by down-regulating Ras via its GAP-related domain (GRD) (Feldkamp et al., 1998). As 
schematized in Figure 2, in the mitogenic signaling pathway, growth factors such as 
· platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) bind to and 
activate their cognate receptors by autophosphorylation of specific tyrosine residues of 
the intracellular domains. Theo adaptor proteins such as Grb2 and Shc recognize the 
specific phosphotyrosine residues by their SH2 (src homology-2) domains or PTB 
(phosphotyrosine binding) domains, and in tum recroit GEFs (guanine nucleotide 
exchange factors) such as Sos to the proximity of its substrate, Ras-GD P. Ras functions 
as molecular switch which is tightly regulated by cycling between an active GTP-bound 
conformation (Ras-GTP) and an inactive GDP-bound state (Ras-GDP). Sos exchanges 
Ras bound GDP for GTP, resulting in activation of Ras and initiation of downstream 
signaling pathway, in particular the mitogenic cascade through Raf kinase, MAPKK 
(mitogen-activated protein kinase kinase), and MAPK (mitogen-activated protein kinase) 
(Feldkamp et al., 1998; Weiss et al., 1999). 
Ras has a slow intrinsic GTPase activity, converting active Ras-GTP to inactive 
Ras-GDP, that is enhanced by GTPase activating proteins (GAPs) which thereby actas 
negative regulators of Ras. The NF 1-GAP related domain of neurofibromin accelerates 
the conversion of Ras-GTP to Ras-GDP, and thus down regulates Ras activity (Shen et 



















Figure 2. Schematic representation of the Ras-Raf-MAPK mitogenic signaling pathway. This 
cascade is activated in normal cel ls when ligand (a growth factor such as platelet-derived growth factor) binds its 
cognate surface receptor (Step !). Ligand-receptor interaction results in receptor dimerization (Step 2), and trans-
autophosphorylation of tyrosine residues on the intrace llular doma in of the receptor (Step 3) . This allows signaling 
molecules (Shc, Grb2) to internet with the phosphotyrosine residues, bringing the nucleotide exchange factor Sos in 
proxim ity to the cell surface, where it exchanges GDP with GTP, activating Ras . Raf interacts with act ivated Ras-GTP, 
and phosphorylates MAPKK. MAPKK then subsequently phosphorylates MAPK. MAPK translocates to the nucleus 
where it participates with other molecules in activating transcription by the transcr iption factors such as Fos and Jun, 
resulting in the increased transcription of genes involved in cell division and other fonctions (Step 4). MAPPK: 
mitogen-activated protein kinase ki nase; MAPK: mitogen-activated protein kinase; MEK: mitogen extracellular signal 
related kinase; ERK: extracellular signal related kinase. 
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The NF 1 gene knockout studies support that NF 1 gene functions as a tumor 
suppressor gene. The heterozygous Nfl +/- mice which possess a single functional Nfl 
allele, mice succumbed to tumors appeared earlier and with higher frequency compared 
to wild type animais (Jacks et al., 1994; Cichowski et al., 1999; Vogel et al., 1999). The 
chimeric mice composed in part of Nfl -/- cells develop neurofibromas (Cichowski et al., 
1999), and mice that carry linked germline mutations in Nfl and p53 develop malignant 
peripheral nerve sheath tumors (Vogel et al., 1999). The homozygous Nfl -/- knockout 
mice were embryonically lethal between days 12.5 and 14 of gestation, demonstrating the 
importance of neurofibromin in cellular growth and differentiation (Jacks et al., 1994; 
Brannan et al., 1994 ). A neurofibrosarcoma from a NF 1 patient bas a homozygous 
inactivation of NFJ (Legius et al., 1993). Both alleles of the NFJ gene are inactivated in 
leukemic cells in 5 out of 18 children with NF l, explaining that the risk of malignant 
myeloid disorder in children with NFl is 200-500 times of the normal risk (Side et al., 
1997). A NF 1 patient with a germline deletion of at least exons 39-45 of the patemal 
allele and the maternai copy deleted in the tumor suggests that NF 1 inactivation is 
involved in the development or progression of some tumors (Martinsson et al., 1997). 
1.1.4 The NFJ gene mutations 
About 30-50% ofNFl patients represent de-novo germline mutations, implying a 
high rate of spontaneous mutation in the NF 1 gene. This mutation rate bas been estimated 
at l mutation per 10,000 alleles per generation, a rate 10-1 OO times higher than the usual 
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mutation rate for a single locus. This may be due to ( 1) the large gene size, (2) 
palindromes, symrnetrical elements, and runs of repeated sequences with preferential 
occurrence of insertions and deletions, (3) the homonucleotide repeats or CpG 
dinucleotides (because 5-methylcytosine in CpG dinucleotides often undergo 
spontaneous deamination), (4) gene conversion between homologous pseudogenes on 
chromosomes 2, 12, 14, 15, 18, 20, 21 and 22 and NF! (Colman and Wallace, 1994), (5) 
germ-line mosaicisms which would elevate the apparent but not actual mutation rate 
(Friedman, 1999). 
The techniques for the detection of NFI mutations are listed in Table 3. Mutation 
analysis in the NFI gene is difficult due to several factors: (1) the large gene size, (2) the 
presence of the normal allele, (3) the high mutation rate and subsequent mutations in 
most families, (4) wide variations in the size a'ld type of mutations (from complete 
deletion of the locus to missense point changes), and (5) homologous loci on other 
chromosomes (Colman and Wallace, 1994). 
T o date, over 1 OO NF 1 germline mutations have been reported to the International 
NF 1 Genetie Analysis Consortium (Shen et al., 1996). A total of 190 germline mutations 
have been reported to the Human Gene Mutation Database at Cardiff. In these 190 
mutations, 52 are missense or nonsense mutations, 28 splicing mutations, 50 small 
deletions, 27 small insertions, l small insertion-deletion, 26 gross deletions, 2 gross 
insertions and duplications, and 4 complex rearrangements (including inversions). The 
occurrence of an identical nonsense mutation in several unrelated individuals has been 
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Table 3. Techniques used to detect and characterize NFJ mutations 
Techniques Types of mutation 
Microsatellite and RFLP (Restriction fragment length Deletion 
polymorphism) marker analysis 
Southern blot hybridiz.ation Deletion 
Cloning and sequencing Point mutation 
FISH (Fluorescence in situ hybridiz.ation) Gross deletion and 
Somatic cell hybrids chromosome rearrangement 
PFGE (Pulsed field gel electrophoresis) 
Heteroduplex (HD) and SSCP (Single strand conformation Point mutation, deletion 
polymorphism) analysis 
Protein truncation test (PTT) Truncated neurofibromin 
DGGE (Denaturing gradient gel electrophoresis) Point mutation, deletion 
Mismatch cleavage: chemical or enzymatic Point mutation, deletion 
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reported. Ail these patients have the same c~ T transition in exon 3 1, changing an 
arginine codon to a stop codon. However, mutations at this locus occur relatively 
infrequently (Colman and Wallace, 1994). About 60% of the NF/ germline mutations are 
predicted to result in truncated neurofibromin presumably due to nonsense or frameshift 
mutations. Large deletions of the gene, which account for about 4-7% of cases, are 
predominantly of maternai origin due to recombinations during oogenesis (Carey and 
Viskochil, 1999). About 90% of ail NF 1 mutations are of paternal origin including the 
majority of point mutations and small deletions. This is probably due to male germ cells 
undergoing more divisions d•Jring spermatogenesis. It bas been suggested that gross 
deletions are commonly associated with distinct manifestations such as learning 
disability/mental retardation, dysmorphie features, neurofibroma, and developmental 
delay (Upadhyaya et al, 1998; Upadhyaya et al, 1996; Cnossen et al, 1997; Tonsgard et 
al, 1997; Wu et al, 1997; Leppig et al, 1997; Valero et al, 1997; Riva et al, 1996; Kayes et 
al, 1994; Kayes et al, 1992; ). However, large NFJ deletions may not always be 
associated with unusual clinical features (Rasmussen et al, 1998). So far, no mutation 
hotspot bas been identified in the NFJ gene. Also no significant genotype-phenotype 
correlation based on the location and type of mutation bas been documented. 
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1.2 Pre-mRNA splicing and exon defmition 
Splicing of nuclear pre-mRNAs occurs in two-steps (Figure 3) (Lührmann et al., 
1990). It involves snRNP (small nuclear RNA-protein) complexes and non-snRNP 
splicing factors (proteins only). In mammalian cells, the major snRNPs are Ul, U2, U4, 
U5 and U6. One of the roles of some spliceosomal snRNPs is the recognition and binding 
of the short consensus sequences in the intron (Lührmann et al., 1990). The snRNPs 
assemble in an apparently ordered fashion onto the pre-mRNA to form a large complex, 
the spliceosome, where splicing occurs. Spliceosome formation (Figure 4) is initiated by 
two pre-mRNAfsnRNP interactions: Ul snRNP binds to 5' splice site, while U2 binds to 
the region of the intron encompassing the branch point, both before and after the branch 
bas been formed. U l snRNP binds to 5' splice site in an A TP-independent manner. Base-
pairing between the 5' end of Ul snRNA and the complementary 5' splice site is one 
essential element of this recognition process. SnRNP proteins are also required for 
efficient Ul snRNP/5' splice site complex formation. The binding of U2 RNP to the 
branch point is A TP-dependent and requires at least the U2AF protein and possibly 
several others. U2AF consists of two polypeptides of a parent molecular weight 35 and 
65 kd. U2AF65 preferentially binds to the polypyrimidine tract at the 3' splice site. U2 
snRNP is then recruited to the U2AF/pre-mRNA complex, probable through direct 
interaction with pre-mRNA-bound U2AF. This is followed by the stable interaction of 
U2 snRNP with the branch point. Following interaction of snRNPs Ul and U2 with the 
intron, snRNPs U4/U6 and U5 assemble into the spliceosome, most likely in the form of 
a 25S U4/U5/U6 tri-snRNP complex. U4 and U6 primarily interact via base pairing, 
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Figure 3. Schematic representation of the two-step splicing reaction. (A) Consensus 
sequences in the mammalian intron, including 5' splice site with an invariant GU, 3' 
splice site of an invariant AG, and the branch point of an invariant A. N represents any 
nucleotides and Py the pyrimidine tract. (B) The two steps of the splicing reaction. The 
first step involves cleavage at the 5 ' splice site and the formation of a 2 ' -5 ' 
phosphodiester bond between the 5'-terminal G residue of the intron and an A residue 
normally located between 18 and 40 nucleotides upstream of the 3' splice site, namely 
the branch point. Thus, the intermediates of the splicing reaction, the cleaved exon 1 and 
the intron-exon 2 lariat are formed. The second step involves cleavage at the 3' splice 
site, ligation of the two exons, and release of the intron which is still in the form of a 
lariat. 
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Figure 4. The sequential integration of snRNPs into the spliceosome. The Ul 
snRNP binds to the 5' splice site of the pre-mRNA and U2 binds to the 3' splice site 
region encompassing the branch point, forming the complex A, then followed by tri-
snRNPs U4/U6.U5 assembled into the spliceosome. A represents branch point, and Py 
pyrimidine tract. 
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while US snRNP probably interacts with U4/U6 through protein-protein contacts. Only 
when all snRNPs are integrated into the mature spliceosome can splicing occur 
(Lührmann et al., 1990). 
Splicing of small exons from large introns in vertebrates has been postulated to 
occur via exon definition. The exon definition model (Figure 5) proposes that in pre-
mRNAs with large introns, the splicing machinery searches for a pair of closely spaced 
splice sites in an exonic polarity. When such a pair is encountered, the exon is defined by 
the binding of Ul and U2 snRNPs and associated factors to 5' and 3' splice sites 
respectively. The binding of Ul to 5' splice site can help define the upstream 3' splice 
site. U2AF65 binds to the polypyrimidine tract at the 3' splice site, then recruites U2 
snRNP probable through direct interaction. U2 snRNP forms stable interaction by base-
pairing with the branch point. This process requires SR proteins which mediate an 
interaction between U2AF35 and U 1 snRNP 70 k protein. The protein-protein contacts 
involved in the 70K-SR-U2AF35 bridging interaction are mediated by serine-arginine 
domain (SR). This process defines an exon. The best-characterized mammalian SR 
proteins are U2AF (U2 auxiliary factor), ASF/SF2 (alternative splicing factor/splicing 
factor 2), and SC35 (35-KD spliceosomal component). Ali three proteins have two 
functional subdomains: RNA-recognition motif (RRM) and serine-arginine rich domain 






Figure 5. Exon definition in pre-mRNA with small exons and large introns. Ul 
snRNP base-pairing with the 5' sp lice site stimulates U2AF65 bound to the 
polypyrimidine tract, and recruiting U2 snRNP to the brance site. U2 snRNP base-
pairs with the brance site. This process is mediated by SR proteins through interaction 
with U2AF35 and Ul snRNP 70K protein. This process defines an exon. SS, splice 
site; Py, polypyrimidine tract; SR, serine-arginine-rich proteins. 
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The efficient recognition of splicing sites is crucial for maintaining the precision 
and order of intron removal in constitutive splicing units. Evidences support exon 
definition in veterbrate from several observations. (1) Introns preceding artificially long 
exons are not spliced. (2) Ul snRNP is required for initial recognition of 3' splice sites. 
(3) The presence of a 5' splice site within an exon affects splicing of the upstream intron. 
(4) Mutations that decreases the match of splice sites to consensus sites often promote 
exon skipping or the use of aberrant splice junctions (Treisman et al., 1983; Moore et al., 
1993; Berget, 1995; Chabot, 1996). In contrast, evidence exists to suggest that pre-
mRNAs with small introns use the intron, rather than the exon, as the initial mode of 
pairing between splice sites (Berget, 1995). 
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1.3 Linkage disequilibrium 
Genes present on the same chromosome are said to show linkage. Linked genes 
tend to be inherited together. We assume that the particular alleles for different loci on a 
chromosome are independent of one another. The alleles at linked loci will be associated 
randomly is known as linkage equilibrium. When alleles are in linkage equilibrium, the 
allele frequency distribution follows Hardy-Weiberg equation: (p+q)2 = p2+2pq+q2=1. 
However, some particular sets of alleles are more likely to be associated nonrandomly. 
The nonrandom association of alleles at linked loci is referred to as linkage 
disequilibrium (LO). Linkage disequilibrium is a population-based phenomenon and 
reflects the effects of recombination over many past generations in the genomic region of 
interest (Feingold, 1991; Zubay, 1987; Korf, 1996). Three types of LD are considered: 
LO between polymorphie markers, LO in the whole population, LO within a family that 
is usually refered as linkage. Both linkage and linkage-disequilibrium measures a co-
segregation between a genetic marker and the disease. Linkage focuses on a locus and 
linkage disequilibrium on an allele. Linkage analysis has the potential to localize a gene 
to a region of about l-2 cM, while linkage disequilibrium operates over a smaller region 
and may be observed in a region of 0.5 Mb in RFLP systems or l Mb for highly 
polymorphie microsatellite markers. Linkage analysis examines the evidence of co-
segregation of a marker and the disease within the families, while linkage disequilibrium 
analysis examines association between a marker allele and the disease in the whole 
population. Linkage results from recombination events in the last 2-3 generations. 
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Linkage disequilibrium results from much earlier, ancestral recombination events (Li, 
1998;.Higgins et al., 1998; Martin, 2000). 
Linkage disequilibrium may be created when a disease is first introduced into a 
population either by a new mutation or an immigrant individual. At this time, linkage 
disequilibrium is complete because there is exactly one haplotype containing the disease 
gene, so for every marker locus in the haplotype there is a unique allele associated with 
the disease. Linkage disequilibrium may also arise in the absence of a founder individual 
due to either population admixture or genetic drift. The latter may be important in small, 
old, isolated population. As generation pass and the number of disease chromosomes 
descended from the founder individual grows, recombinations occur between the disease 
and marker loci, decreasing disequilibrium. Since the recombination factor is 
approximately proportional to physical distance, linkage disequilibrium decays faster for 
markers further from the disease locus. It is this fact that allows the relative position of 
the disease gene to be estimated and the founder to be traced (Martin et al., 2000; 
MacLean et al., 2000). 
Computer programs have been developed for linkage and linkage disequilibrium 
analysis. They are based on the basic statistical philosophy: hypothesis test or 
significance test. First a null hypothesis is proposed. Then some appropriate test 
criterions are calculated from the sample values. The criterion distribution is also 
calculated under the null hypothesis. By comparson the criterion distribution, the 
significance level will become clear. The most used criterion value is p-value. It is a 
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common (but arbitrary) convention to consider p-value greater than 0.05 as 'not 
significant'. We usually consider O.Ol<p<0.05 as significant; O.OOl<p<0.01 as highly 
significant; p<0.001 as very highly significant (Elston and Johnson, 1990). 
Recently, whole-genome linkage disequilibrium studies to map common disease 
genes have been investigated. lt uses a dense map of single nucleotide polymorphisms 
(SNP) to detect association between markers and disease. Construction of SNP maps is 
currently underway and approximately 500,000 SNPs will be required for whole-genome 
studies (Kruglyak, 1999). 
Linkage disequilibrium has been investigated in many diseases, such as X-linked 
juvenile retinoschisis (Huopaniemi et al., 1997), multiple endocrine neoplasia type 1 
(Bassett et al., 1997), and Niemann-Pick disease (Greer et al., 1999). Linkage 
disequilibrium bas been applied for mapping many genes, such as, Salla disease gene 
(Schleutker et al., 1995), Ataxia with vitamin E deficiency gene (Doerflinger et al., 
1995), Werner Syndrome gene (Goddard et al., 1996), dominant optic atrophy locus 
(Votruba et al., 1998), and Batten disease gene (Mitchison et al., 1995). Sorne 
anonymous genomic regions have also been studied by linkage disequilibrium 
distributions which provide information for genetic mapping and for investigation, at the 
population level, of the processes such as recombination, selection, and mutation 
(Peterson et al., 1995; Kendler et al., 1999). 
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Linkage disequilibrium among RFLPs in the NF 1 region bas been previously 
reported in Spanish and Italian population (Jorde et al., 1993; Messiaen et al. 1993; 
Valero et al., 1996, Purandare et al., 1996; Natacci et al., 1999). A high degree of 
disequilibrium is maintained among seven NF! intragenic polymorphisms (r > .82, p < 
10·1), even though they are separated by as much as 340 kb (Jorde et al., 1993). Three 
intragenic polymorphie microsatellite markers, AAAT Alu repeat, IVS27ACl27.2 and 
IVS38GT53.0, exhibit linkage disequilibrium between each other (Valero et al., 1996). 
Five polymorphisms in the NF! gene also showed lack of independence (Messiaen et al., 
1993). 
Here in this thesis, 1 report the identification and characterization of a splicing 
mutation which causes skipping of both exons 11 and l 2a, and six gross deletions in the 
NF! gene. In addition, a Hincll polymorphism bas been detected in the 5' region of the 
NF! gene and linkage disequilibrium in the Québec population has been analyzed using 
the haplotype data. 
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CHAPTER 2 MATERIALS AND METHODS 
The experimental design is depicted in Figure 6. Blood samples were collected 
from the NFI patients and the members of their families. DNA or RNA was extracted. 
The haplotypes were constructed with six polymorphie markers (Table 4) and analyzed 
statistically for linkage disequilibrium. The loss of heterozygosity (LOH) analysis was 
performed to identify deletions. The deletions were further characterized by Southern blot 
analysis. At the same time, the protein truncation test (PTT) was performed to detect 
mutations affecting neurofibromin. One neurofibromin mutation (5313) was further 
characterized by sequencing, in vivo and in vitro splicing analysis. 
2.1 NFl Patients and NFl families 
Ail patients diagnosed with NF l fulfilled the diagnostic criteria as described in 
the NIH Consensus Development Conference Statement (Stumf et al., 1988) and gave 
informed consent for a molecular study oftheir DNA. 
A total of 19 family and 20 non-family cases from Québec, Canada was used. The 
19 NF l families (total 87 persans: 45 NF l patients and 42 normal individuals) include 15 
family cases and 4 sporadic cases. In these 19 families, l 6 families are two-generations 
and 3 are three-generations. Ali f amilies are unrelated and corne from different regions of 
Québec, representing an apparently random sarnple of the population. The 20 non-family 
cases were made of individual NFI patients with no family records available. 
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Figure 6. Schematic chart of the experimental design. Blood samples were obtained 
from the NFl patients and the members of the NFl families. DNA or RNA was 
extracted. Polymorphie markers were amplified by PCR for linkage and loss of 
heterozygosity analysis. DNA was analysed by Southern blotting. RNA was used in the 
protein truncation test. The exon skipping mutation (5313) was further characterized by 
cloning, sequencing, in vivo and in vitro splicing analysis. 
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Table 4. Cbaracten of polymorphie marken used in baplotyping 
Polymorphie r\farkcrs Gcnomic Fragment 
type localisations lcngths 
RFLP Eco RI Exons l-4a 7 .3 kb, 4.2 kb in Southern blots 
RFLP Rsal Exon 5 500 bp, 450 bp, 300 bp, 50 bp 
Microsatellite IVS26-2.3 Intron 26 =206 pb 
Microsatellite IVS27 AC28.4 Intron 27b =213-225 pb 
Microsatellite IVS27AC33.l Intron 27b =104-124 bp 
Microsatellite IVS38GT53.0 lntron 38 =171-187 bp 
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For the Hincll polymorphism study, 67 unrelated persons from Québec including 
14 NFI patients and 53 unaffected individuals (who are not from the above mentioned 
NFI families) were analyzed for allelic frequencies by Hincll digestion of the genomic 
DNA. 
NFI patients and families were identified in the following hospitals and clinics: 
Dr. Bernard Lemieux from Département de Pédiatrie du Centre universitaire de santé de 
l'Estrie (CUSE), Ors. Ortenberg and Rouleau from Montreal Children's Hospital, and Dr. 
Ruest from Centre hospitalier de Rimouski. 
Three NFI families: 7610, 7473 and 5313 were studied extensively. Their 
clinically features are as follows. With family 7610, a 5 year old boy (II-1) and bis 
mother (I-1) were diagnosed with NFI. When the mother was examined at 36 years old, 
more than 6 café-au-lait spots with sizes larger than 15 mm were present on the trunk and 
the limbs. Sulky café-au-lait spots around the neck were excised for cosmetic reason. 
Multiple under-cutaneous nodules and neurofibromas, but not plexiform neurofibroma 
were observed. Many ephelises on axillary bilateral region, Lisch nodules and a light 
scoliosis of the column in the dorsal part were observed. When she was 33 years old, 
arterial hypertension started to appear. In etiologic surgery, detachment of the bottom part 
of the retina was observed. The son (II-1) is the only child of the woman (I-1) who bas 
not had an abortion. The pregnancy and the labour were both normal. A convulsion 
happened at the second day of the birth. One week after birth, the boy was noted to have 
a few café-au-lait spots. At 5 years old, the growth and development of the boy was 
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normal except for some pronunciation troubles. Cephalalgia was absent and there was no 
visual trouble. The cranial nerves including the back of the eye, the visual field and the 
pupil reflex were normal. No Lisch nodule was observed. More then 6 café-au-lait spots 
with sizes larger than 5 mm were observed on the trunk and the limbs. Café-au-lait spots 
were also present on the ephelises of auxiliary inguinal bilateral region. Three under-
cutaneous neurofibroma on posterior trunk and fold of buttock were noticed. No 
plexiform neurofibroma, bone lesion, limbs and face abnormality, proptosis and scoliosis 
were observed. The grandfather and one aunt of the boy were also reported possibly with 
NFl. The father (I-2) was normal. In family 7473, a 36-year-old woman (II-1) and her 
two daughters (III-1 and Ill-2) were diagnosed with NFI at the age of 32 for the woman 
and 3 and 4 for the two daughters. The woman had multiple café-au-lait spots from birth. 
The first neurofibroma appeared during her puberty. Her grand parents, parents, sister 
and brother were healthy. In family 5313, the mother (I-2) and her two sons (11-1and11-
2) were NFI patients. Numerous café-au-lait spots and small cutaneous neurofibromas 
were diagnosed from these three NFI patients. The father (I-1) was normal. 
2.2 Collection of blood samples and separation of leucocytes from blood 
About 30-40 ml of blood was collected per person: l 0 ml in a sterile ac id citrate 
dextrose tube for cell transformation, 20-30 ml in either EDT A or ACD tube for DNA 
isolation. For children, 4 or 5 ml of blood samples were collected. Blood samples were 
kept at room temperature or at 4°C. Leucocytes were isolated from whole blood by 
Ficoll-hypaque gradient centrifugation. About 5 ml of blood was laid on the top of 5 ml 
27 
ofHISTOPAQUE-1077 (Sigma) solution and centrifuged. After removing the top plasma 
layer, leucocyte cells were transferred to a fresh tube. Red cells were lysed in hypotonie 
0.2 % NaCl solution and then treated in hypertonie 1.6 % NaCl to restore the ionic 
strength. The leucocytes were collected by centrifugation, resuspended in PBS buffer and 
kept at -20°C. 
2.3 Cell Culture 
Lymphoblastoid cell lines from members of NFl family were established by 
Louise LeBuis in Dr. Rouleau's laboratory (Montreal General Hospital) by Epstein-Barr 
virus transformation of mononuclear cells from the peripheral blood in the presence of 
cyclosporine A (0.1 µg/ml in culture). Cells were cultured in ISCOVE medium (Gibco 
BRL) with 10 % fetal bovine serum (FBS) and 5 % C02 at 37°C. Adherent cells (HeLa) 
were grown in Dulbecco modified Eagle medium (DMEM; Gibco-BRL) supplemented 
with 10% newborn calf serum in 5% C02 at 3 7°C. Cells were seeded at O. 7 x 106 
ce li/plate in 100-cm-diameter plates. Cells were split 1 :5 every 3 days in 100-mm-
diameter plates. 
2.4 Extraction of DNA and RNA 
Genomic DNA was extracted either from about 2 x 106 leucocyte cells or from 
lymphoblastoid cell lines by standard phenol-chloroform method (Sambrook et al., 1989). 
Cells were first treated with 200 µg/ml of proteinase K at 55°C overnight in NE buffer 
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(105 mM NaCl, 26.38 mM EDTA, pH 8). Then an equal volume of phenol was added to 
the solution. After shaking and centrifugation, the top phase was transferred to a fresh 
tube and extracted once with equal volume of phenol-chloroform-isoamyl alcohol 
(25:24:1), and twice with chloroform. DNA was precipitated with 2 volume of 95 % 
ethanol, washed and suspended in TE buffer or bidistilled water. The concentration of 
DNA was measured at O.D. 260 nm as 50 µg DNA/ml/OD and examined by agarose gel 
electrophoresis with ÀDNA/ HindlII as a standard. 
Total cellular RNA was extracted with TRizol reagent (Gibco BRL). About 106 
cells were collected by centrifugation and resuspended in l ml of TRizol. After 
incubation for 5 mins at room temperature, 0.2 ml of chloroform was added and the 
mixture vortexed. After 5 mins at room temperature, the mixture was centrifuged. The 
RNA was precipitated with isopropanol and resuspended in DEPC-treated H20. The 
concentration of the RNA was measured at O.D. 260 as 40 µg RNA/ml. 
2.5 PCR, cloning and sequencing of the genomic l l-12a region of patient 5313 
With patient 5313, three NF/ genomic fragments: exon 11, exon 12a and exon 
l l- l 2a, were amplified by PCR with intronic primers (Li et al., 1995). Exon 11 was 
amplified with primers: forward 5' GTA CTC CAG TGT TAT GTT TAC C 3' and 
reverse 5' TAA AGT TGA AAT TTA AAA ATT AAA GTA C 3'. Exon 12a was 
amplified with primers: forward 5' AAA CCT TAC AAG AAA AAC T AA GCT 3' and 
reverse 5' ATT ACC ATT CCA AAT ATT CTT CCA 3'. The l l-12a region (from 
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intron lOc to intron 12a) was amplified by primers: forward 5' GTA CTC CAG TGT 
TAT GTT TAC C 3' and reverse 5' ATT ACC ATT CCA AAT ATT CTT CCA 3'. The 
amplifications of exons 11 and 12 were 5 mins at 96°C, 35 cycles of l min at 93°C, 1 min 
at 53°C, and l min at 72°C, and finally l 0 min at 72°C. The amplification protocol of l l-
l 2a was the same as for exon 11 and exon l 2a except that the annealing temperature was 
s1°c. 
The PCR products of the genomic l l-12a fragment (from intron lOc to intron 
12a) of both wild type (wt) and mutant (mut) were blunted with DNA polymerase 1 
Klenow fragment and ligated into pUC18 at Smal site to generate pUCl l-12a. The 
ligation was in a total volume of 15 µl containing no less than l OO ng of insert, 50 - l OO 
ng of plasmid, l mM ATP, l mM dNTP, and l u T4 DNA ligase. The ligation mixture 
was incubated at room temperature for at least 6 hr. E. coli DH5a was transformed by 
heat shock at 42°C for 2 min. Recombinants were selected on plates with l OO µg/ml of 
ampicillin, X-Gal and IPTG. White colonies were grown in LB media with 100 µg/ml of 
ampicillin and with shaking ovemight at 37°C. Plasmid DNA was prepared by mini-preps 
(Sambrook et al., 1989). The insertion was checked by restriction digestion and 
sequencing. Sequencing was performed using a T7 Sequencing kit (Amersham) 
following manufacturer's instructions. Briefly, templates were denatured with IO N 
NaOH at room temperature for l 0 min. Sequencing primers were annealed to templates at 
65°C for l 0 min. The elongation was with T7 polymerase at room temperature for 5-7 
min with incorporation of [a-32P]dCTP and terminated with ddNTP. The radio-labeled 
products were separated by electrophoresis in a 8% denaturing acrylamide-urea gel with 
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1 x TBE using a constant power of 45 W. Gels were autoradiographed at room 
temperature for 1-16 hr. 
2.6 Amplification of the polymorphie regions by PCR, baplotyping and statistical 
analysis 
2.6. l Microsatellites 
The microsatellite allelic regions at intron 26 (IVS26-2.3), intron 27 
(IVS27 AC28.4 and IVS27 AC33. l) and intron 38 (IVS38GT53.0) were carried out as 
described (Andersen et al., 1993; Lazaro et al, 1994; Lazaro et al, 1993) with minor 
modifications. The PCR was in a total volume of 20 µl containing 0.5 µM dNTP, 0.5 µM 
of each primer, 1 u Taq polymerase, 5 µCi of [a-32P]dCTP (Amersham 3000 Ci/mmol) 
and 1 OO ng of genomic DNA. The amplification was 5 mins at 94°C, then 27 cycles of 20 
sec at 94°C, 20 sec at the appropriate annealing temperature (see Table 5), and 30 sec at 
72°C plus l second per cycle followed by a final elongation for 7 min at 72°C. The 
amplified fragments were analyzed on a 40 cm 8 % denaturing acrylamide-urea gel. The 
sizes of the allelic fragments were determined by comparison with a pUC 18 sequence 
ladder prepared with a T7 Sequencing kit (Amersham). 
2.6.2 Rsal RFLP 
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Table S. PCR Conditions and sequences of the microsatellite primers 
Locus Primers Type of Annealing Alle lie 
repeats temperature sizes 
(bp) 
IVS26-2.3 F 5' -AGGCCAGGAGTTCAAGACCA-3' (TAGA), 58uC 204-226 
R 5'-ATGAGCCACTGTGCCCAA TC-3' (TAGG), 
(TAAGA) 
IVS27 AC28.4 F 5' -TGAAGT A TGCAGITITCCAG-3' (CA) 55uc 215-231 
R 5' -GGCT AAGTGT AAACGCAAAG-3' 
IVS27 AC33. l F 5'-T AGA TT AT A TGGGACAGAAAA TG-3' (CA) 55uC 104-116 
R 5'-CTTGAGGTGATGACAGGATG-3' 
IVS38GT53.0 F 5'-CAGAGCAAGACCCTGTCT-3' (CA)/(GD 52°C 171-189 
R 5'-CTCCTAACATTTATTAACCTTA-3' 
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The RsaI RFLP site of exon 5 was amplified with primers 5E-1 (5'-CAT GTG 
GIT CTI TAT TTA TAG GC-3') and 5E-2 (5'-CCA AGT CAA ATA GCT TTT CTG 
C-3') to yield a 800 bp PCR product which covers exon 5, intron 5 and part of exon 6 
(Hoffmeyer and Assum, 1994). PCR was performed in a total volume of 50 µl containing 
0.4 mM dNTP, 0.2 µM each primers, 2 units ofTaq polymerase and 100 ng of genomic 
DNA. The amplification was 94°C for 5 min, then 35 cycles of l min at 92°C, l min at 
52°C and l min at 72°C, and a final extension at 72°C for l 0 min. Ali PCR products were 
digested with RsaI at 37°C. The digested fragments were separated on a l % agarose gel 
and the sizes of the fragments were determined by comparison with a 1 kb marker. The 
Rsa 1 digests yield a 500 bp and a 300 bp fragments if the restriction site is absent. If 
present, RsaI cuts the 500 bp fragment into a 450 bp and a 50 bp fragments. Since the 50 
bp fragment runs out of the gel, the presence of the 450 bp fragment is indicative of the 
presence of the RsaI site. However, in some cases if there is a deletion (Figure 7), then 
the 450 bp and 50 bp fragments may be present, while the 500 bp fragment is missing as 
with families 7610 and 7473. 
2.6.3 Haplotype analysis 
Haplotypes were constructed manually, assuming a minimum number of 
recombinations in each family. Haplotypes were also redrawn and confirmed using the 
GENEHUNTER program. For ail families the markers were informative at different loci, 
and for each marker the disease-bearing chromosome could be identified. 
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Absent Pre sent Deleted 
500 bp 1 500bp ~ ~ 
1 450 bp 1 1 1 450 bp 1 
Rsal Rsal 
500 bp 500 bp 500 bp 
450 bp 450 bp 
50bp 50 bp 
(1) (2) (3) 
Figure 7. The Rsal polymorphism in exon S. Exon 5 region was amplified by 
PCR and digested with Rsal (represented by small vertical lines). If the Rsal site 
is not present, 500 bp band is detected (1). When the site is present, Rsal eut the 
500 bp fragment to 450 bp and 50 bp fragments (2). However, if one of the sites is 
deleted, 450 bp and 50 bp fragments are present, while 500 bp fragments are 
missing. 
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2.6.4 Statistical analysis 
The allele frequency was calculated. We sampled alleles only in "founders" 
(parents and married-ins). Children do not provide independent samples, since they 
derive their alleles from the parents. A total of 79 'founders' were used in the analysis. 
The frequency distribution of alleles on disease-bearing and non-disease-bearing 
chromosomes was analysed using all 19 pedigrees. Affected individual bearing the full 
disease haplotype from 19 families was selected for analysis. This gave rise to a total of 
27 affected haplotypes (chromosomes) to be included in the analysis. The 52 unaffected 
individuals were taken as controls for the assessment of normal population allele 
frequency, giving rise to a maximum of 104 chromosomes. 
Linkage analysis between the disease and markers was carried out using the 
computer program LINKAGE [Terwilliger and Ott, 1994] and GENEHUNTER 
[Kruglyak, et al, 1996]. Such a linkage analysis is necessary to ensure that the regions 
being focused on are indeed related to the disease. Logarithm (base 10) of the likelihood 
ratio, between that of linkage under the given disease model ( e.g., dominant) and that of 
no linkage, is called the LOD score. A LOD score of 3 is usually used as a strong 
evidence for linkage. LINKAGE program is used for a two-point analysis (i.e., each 
marker is analyzed separately); and GENEHUNTER is used for multi-point analysis (i.e., 
all markers are considered at the same time ). 
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Unlike linkage analysis which examines the evidence of co-segregation of a 
marker and the disease within the families, linkage disequilibrium analysis examines 
association between a marker allele and the disease in the whole population. Such 
association is present when there is only one or a few disease haplotype at the time the 
mutation was first created (founder effect), and if the marker is close enough to the 
disease locus. We use the computer program HAL (currently renamed TRIMHAP) 
[MacLean et al., 2000] to examine whether there is evidence for such founder haplotype. 
The null hypothesis that founder haplotype does not exist is tested, and the test result is 
presented by a p-value. 
Another population-based association analysis is carried out by the DISEQ 
program [Terwilliger, 1995]. In this approach, the assumption that some alleles are 
abundant is tested by a likelihood ratio test as well as the standard x2 test. Again, p-value 
for the null hypothesis of no association between the disease and a marker is obtained. 
Association can be established only when the p-value is small. 
In-between the linkage analysis within a family and linkage disequilibrium 
analysis within a population, there is a third type of analysis called family-based 
association analysis. Family-based association examines both linkage and linkage 
disequilibrium in parents-affected-child triads. Either lack of the co-segregation between 
the marker and the disease within the pedigree or lack of association between the marker 
alleles and the disease in the population will render the test insignificant. We used the 
GASSOC program [Schaid, 1996]. Generalizing the popular transmission/disequilibrium 
36 
test (TOT) (Spielman et al., 1993], this program uses a likelihood ratio test with the 
incorporation of a disease model. As a result, tests under dominant and recessive disease 
models can be analyzed separately (on the other hand, TDT is a non-parametric test 
without the specification of the disease model). 
Linkage disequilibrium between markers is determined by a Monte Carlo version 
of the Fisher's exact test. In a Fisher's test, the joint count table of alleles at two markers 
is constructed from the haplotype data. Ali other possible joint count tables with the same 
column and row margins can be in principle enumerated, and from the distribution of 
these tables, p-value of any test statistic can be calculated. Rather than enumerating ail 
tables, we randomly sample 100,000 tables, and an approximate p-value is determined. 
The corresponding p-value for a xz test is also included, which is correct in the large 
sample limit. 
Ali computer programs mentioned above are listed in the webpage: 
http://linkage.rockefeller.edu/soft/, and their distribution addresses (URL's) can be traced 
accordingly. 
2. 7 Southern blot, Eco RI and Hincll polymorphism 
The seven cDNA probes: GE2, FF13, FFI, FB5D, P5, and B3A, made of portions 





- GE2, covcrs exons l,2,3,4a 
-----FF13, covcrs cxons 4a,4b,4c,5,6,7,8,9 
1 1.0kb 1 l.4kb 1 
FFI, covcrs exons 7,8,9,IOa.lOb,!Oc,l l,12a,12b,13,l4,IS,16,17,18,l9a..19b,20,21 
970bp 61Sbp S90bp 
FBSD, covcrs cxons l 8, l 9a, 19b,20,21,22,23-l ,23-2,24,25,26,27a,27b,28,29 
AE25, covc:rs cxons 27b,28, 29, 30, 31, 32. 33, 34, 35, 36, 37, 38 
l.IH:b O.SHb 
PS, covcrs cxons 36,37,38,39,40,41,42,43,44,45,46,4i,48,49 
B3A, covers cxons 45,46,47,48,49 
Figure 8. The seven NFJ cDNA probes. The probes encompass the entire coding 
region with overlapping. The proximate positions of the probes related to the NF J 
cDNA are as depicted. Vertical lines on the NFJ cDNA represent EcoRI sites. This 
diagram is not quite to scale. 
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Southern blotting. The cDNA fragments cloned at the EcoRI site in pBluescript were 
obtained from Dr. Wallace's and Dr. Vidaud's laboratories. The plasmids were prepared 
by mini-preps and purified by equilibrium centrifugation in CsCl-ethidium bromide 
gradients (Sambrook et al., I 989). The cDNA probes were obtained by restriction 
digestions. EcoRI and Sacll double digestion of GE2 plasmid gave a I 50 bp piece 
(untranslated region, very G/C rich) and a 400 bp fragment (which includes the ATG and 
spans exons I-4a, overlaps FFI3 by 82 bp). Digestion of the FFI3 plasmid with EcoRI 
gave the 876 bp FFI3 probe. FF13 covers exons 4a-9 and overlaps FFl by 220 bp. 
Further digestion of FF13 (876 bp) with Hinfl gave the FF13 (625 bp) probe which was 
used to fine localize the deletion 7610 breakpoint. The FF13 (625 bp) fragment covered 
I 2 bp of exon 4b and exons 4c-9 (Figure 9). Digestion of FF 1 plasmid with Eco RI and 
Hincll yielded a 1.4 kb (3' hait) and a 1.0 kb (5' hait) fragments, which were used 
separately. The entire FFI fragment is 2625 bp and covers exons 7-21. FFl overlaps the 
970 bp FB5D fragment by 530 bp. Double digestion of the FFl 1.0 kb fragment with 
Haelll and Hpall yielded the FFI (430 bp) probe (Figure 10) which was used in the 
characterization of mutation 53I3. FFI (430 bp) covers exon lOc (98 bp), exons l 1-I2a, 
and exon 12b (128 bp). The entire FB5D fragment is 2177 bp and covers exons 18-29 
which contain the NFJ-GRD domain. Digestion of FB5D plasmid with EcoRI yielded 
three fragments: 970, 615 and 590 bp. The 970 bp fragment is the 5'-most, 615 bp is in 
the middle, and 590 bp is at the 3' end. The 970 bp fragment was used independently. The 
615 bp and 590 bp fragments could not be separated and were used together. EcoRI 
digestion of plamid P5 released two inserts: 1.15 and 0.55 kb (5' and 3' respectively). The 
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A. 
ATG NFL cDNA 
5· ....,x_ ..... _____ ..,.. _____ ----11------4~--····················3· 
---GE2 covers exons l, 2, 3, 4a 
------FFL3, covers exons 4a. 4b, 4c, 5, 6, 7, 8, 9 


















Figure 9. The FF13 876 bp and FF13 625 bp probes for characterisatioo of 
deletion 7610. (A) The relative position of probe GE2 and probe FF13 to the NFJ 
cDNA. Probes GE2 and FF13-876 bp overlap by 82 bp in exon 4a. (B) Digestion 
of FF13 (876 bp) with HintI excludes exon 4a and 95 bp of exon 4b to give FF13 
625 bp probe. 
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FFI (1.0 kb) 
(started from Exon 7) 5' 










Exon lOc 1755 Haelll 
<1R.li3) 
Exon 11 
FFI (430 bp) (1933) 
Exon l2a 
(2057) 
Exon l2b 2185 Hpall 
(2213) 
Exon 13 
'246~) Eco RI 
3' 
Figure 10. The FFI 1.0 kb and FFI 430 bp probes for characterisation of 
mutation 5313. Double digestion of FFI l.O kb with Haelll and Hpall gave the FFI 
430 bp probe. The FFI 430 bp probe covers exon lOc to exon I2b and was used to 
characterise mutation 53 I3. 
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entire P5 fragment is 1700 bp and covers exons 36-49. lt overlaps the B3A fragment by 
500 bp. Digestion of B3A plasmid released a 800 bp fragment which covers exons 45-49, 
the stop codon and some 3' untranslated sequence. 
The digested fragments were fractionated on 1 % low melting agarose gel in 1 x 
TAE buffer. Bands were excised under UV and purified with Wizard™ PCR DNA 
Purification kit (Promega) following the manufacturer's instruction. Briefly, the agarose 
slice was melted at 70°C, and mixed with the resin. Then, the resin/DNA mix was loaded 
onto a Wizard™ minicolumn, spun for 12 sec, and washed with 2 ml of 80% isopropanol. 
The bound DNA was eluted with 50 µlof water. 
The probes were labeled using a Multiprime DNA labeling Kit (Amersham) 
following the manufacturer's instructions. Briefly, about 25 ng of DNA was denatured 
for 5 min and then labeled at 37°C for 1 hr in a total volume of 50 µl containing dATP, 
dGTP, dTTP, and random hexanucleotide primers in the presence of [a.-32P]dCTP 
(Amersham 3000 Ci/mmol, 25 µCi/µl), with 2 u of DNA polymerase 1 Klenow fragment. 
The labeled probes were purified with a Sephadex G-50 spun-column in the presence of 
salmon sperm DNA as carrier (Sambrook et al., 1989). 
Blotting, hybridization and washing were as follows. About 10 µg of digested 
genomic DNA were separated in a 0.7 % agarose gel, depurinated with 0.25 M HCl, and 
denatured with 0.5 M NaOH. The DNA was alkali blotted to Hybond™-W nylon 
membrane (Amersham). The transfer was at room temperature with 0.4 M NaOH for 12-
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24 br. The membrane was pre-hybridized in a solution containing 5x SSC, 5x Denhardt's 
solution, 0.5% SDS and 20 µg/ml of denatured salmon sperm DNA at 65°C in a 
hybridization bag. Hybridization was carried out with labeled probe ovemight at 65°C. 
After hybridization, the membrane was washed with 2x SSC for 20 min at room 
temperature and then with 0.1 x SSC containing 0.1 % SDS at 65°C for 30-60 min, and 
autoradiagraphed. For rehybridization, the membrane was stripped with 0.5% SDS (w/v). 
Both EcoRI and Hincll polymorphisms were detected by Southern blotting with 
probe GE2-400 bp. The Eco RI polymorphism detects two-allele fragments of 7 .3 kb and 
4.2 kb (Reyniers et al., 1993). For the Hincll polymorphism analysis, genomic DNA was 
extracted from 67 unrelated individuals. About l 0-15 µg of genomic DNA was digested 
with Hincll at 37°C for at least 2 hr. 
2.8 Protein truncation test {PTT) 
The PTT is based upon a coupled in vitro transcription and translation assay 
(Figure 11 ). It was performed as described (Heim et al., 1995) with minor modifications 
(Bahuau et al., 1998). Mainly, the entire coding reg ion of the NF 1 gene was amplified in 
nine instead of five overlapping segments by RT-PCR. This has the advantage to produce 
fragments of size between 928 and 1484 bp and thus make the localization of the 
mutation easier. 










ci==== l ln vitro transcription and translation 
W.T. NFl 
SOS-PAGE 
r Truncated protein 
Figure 11. Schematic representation of protein truncation test. RNA is extracted and 
reverse transcribed into cDNA. Specific fragments are amplified by PCR and used as 
templates for transcription. After in vitro transcription and translation, protein products 
are labelled by 35S-methionine and separated on a SOS-PAGE. If there is a mutation 
affecting the protein size, a truncated product will be detected. 
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First, the cDNA was synthesized. About 5 µg each RNA was incubated 10 min at 
65°C followed by 5 min at 25°C in a 50 µl reaction mix containing 0.25 nmol of oligo 
d(T)16 (Perkin-Elmer) and 2.5 mM of random hexamers (Pharmacia). Theo, the above 
reaction mix was adjusted to a final volume of 1 OO µl by adding 1 x Superscript buffer 
(Gibco8RL), 0.5 mM dNTP, 10 mM dithiothreitol (DDT), 20 u RNasin (Promega), and 
100 u Superscript® reverse transcriptase (Gibco-8RL). The reverse transcription was 
incubated at 42°C for 40 min and stopped by heating at 90°C for 5 min. 
Second, a two-step PCR procedure was used to produce 9 overlapping fragments 
(A to 1) covering the entire neurofibromin cDNA (Table 6). Step one used nine pairs of 
primers (Al-A2, 81-82, Cl-C2, etc.) to amplify the entire cDNA. Step two used another 
nine pairs of primers (A3-NFPTT, 83-NFPTT, C3-NFPTT, etc) to further amplify each 
segments. NFPTT primer is common to all fragments (A-1) and contains a T7 promoter 
and a translation initiation site within a Kozak sequence for efficient transcription and 
translation. The primers (A3, 83, C3, etc.) are internai (nested) to the step-one PCR 
product to promote specific amplifications. Step l PCR involved a 50 µl reaction mix 
containing 10 µl of the RT product (about 250 ng cDNA), l x PCR buffer Il (Perkin-
Elmer), 1.5 mM MgCh, 0.1 µM each primer, l u Taq polymerase and 0.2 µl TaqStart® 
Antibody (Clontech). The amplification was 5 min at 94°C, 20 cycles of 30 sec at 94°C, 
30 sec at 55°C, and 1 min at 72°C, and finally 7 min at 72°C. Step 2 PCR was performed 
in a l OO µl reaction mix containing 1 µl of the above PCR product. lx PCR buffer 1 
(Perkin-Elmer), 0.2 mM dNTP, 0.1 µM each primer, 2 u Taq polymerase (Perkin-Elmer), 
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Table 6. Sequences of primers used in PCR for protein truncation test. 
The primers used in PCRl (e.g. Al-A2, 81-82, etc.) include a 3' sequence specific for 
the NFl cDNA and a 5' sequence correspondent to a Kozak sequence and part of the T7 
RNA polymerase promoter (underlined). 
Fragments Exons PCRprimers Sizes of PCR 
products (bp) 
A 1-8 Al 5'CACTATAGGAACAGACCACCATGGCCGCGCACAGGCCGGTGGAAJ' Al-A2 : 1175 
A2 5' ACGAAAGCAAGAAACAAGGCAGTCAJ' 
AJ 5'CA TT AGATCCACATCTGCAGGCTGAJ' A3-NFP1T: 1164 
NFPTT 5'GGATCCT AA TACGACTCACT A TAGGAACAGACCACC3' 
8 6-12a B 1 5'CACTATAGGAACAGACCACCATGAA TAAGAAGTT A TTTCTGGACJ' 81-82 :940 
B2 5' AACCACTTGAGAA TTTCTGTGCTI' 
BJ 5'GCA TTTGATGACTAGTT AA TTTC3' 83-NFPTI: 928 
c IOb-17 C 1 5'CACTATAGGAACAGACCACCATGGTGAAACT AA TTCA T3' Cl-C2 : 1492 
C2 5'GCTTGCCCT AGATGTTCAGAJ' 
CJ 5'GCCTTCAGTATGATTATCTAGCA3' C3-NFP1T: 1485 
D 16-23 D 1 5'CACT ATAGGAACAGACCACCATGGGTCCAGTCAGTGAAJ' Dl-D2 : 1367 
D2 5'TTGCCAATCAGAGGATGTGA3' 
D3 5'TCGTAATAAAGGATCCAGGAGTT3' D3-NFP1T: 1356 
E 21-27b E 1 5'CACTATAGGAACAGACCACCA TGGGTGATCAAGGAGAACTCCJ' El-E2 : 1336 
E2 5'CGA TTGCTAGGCCCGGTATGJ' 
EJ 5'CA TTGA TTTGACCAGTTTTGAA3' E3-NFP1T: 1252 
F 27a-32 FI 5'CACT A TAGGAACAGACCACCA TGGCAACACTTCTTGCATAC3' Fl-F2 : 1528 
F2 5'CCAGAAGCCAAAGCTACAGC3' 
FJ S'CCTGTTGCACTGGTITIGATGAJ' F3-NFP1T: 1484 
G 31-38 G 1 5'CACTAT AGGAACAGACCACCA TGACTCCATGGCTGTCAAJ' Gl-G2 : 1186 
G2 5' AGTGCGGTACCTGCTGAATACJ' 
G3 5'GCCACAGCTACCCAAAAGAAG3' G3-NFP1T: 1154 
H 35-44 Hl 5'CACT AT AGGAACAGACCACCA TGAGAGATA TTCCAACGTG3' Hl-H2 : 1199 
H2 5'CCTGGATCTTCGGATCAGTAA3' 
H3 S'CGTAAATGTGGGTGCTGTTGTJ' H3-NFP1T: 1147 
42-49 11 S'CACT ATAGGAACAGACCACCATGGGGCAA TCTTCTCAGGJ' 11-12 : 1090 
12 5'CAAGGACAGGGAAGGGGTCACT3' 
13 5'GTGAAGAGCCCATGTT AAGTTGJ' 13-NFPTI: 1083 
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and 0.4 µl TaqStart® Antibody (Clontech). The amplification was the sarne as in step 1 
except for the number of cycles (25x). 
2.8.2 In vitro transcription and translation 
In vitro transcription was performed using T7 Cap-Scribe® kit (Boehringer 
Mannheim). The entire PCR step 2 product ( 100µ1) was purified with a column 
Microcon® 30 (Amicon), recovered with 14 µl H20/DEPC (0.1 % v/v), with addition of 4 
µI 5x CapScribe® buffer and 40 u T7 RNA polymerase for a final volume of 20 µI. The 
reaction mix was incubated 1 hr at 3 7°C. Reaction was stopped by placing the reaction 
tube on ice. In vitro translation was performed with 2 µI of each of the above 
transcription product using the Reticulocyte Type I® kit (Boehringer Mannhein), 
following the manufacturer's instructions, and labeled with 35S-methionine (1,000 
Ci/mmol, Amersharn). The translation products were separated by SOS-PAGE. The gel 
was dried and autoradiographed. 
2.8.3 cDNA sequencing 
The cDNA sequencing was carried out using the ABI PRISM® Oye Terminator 
Cycle Sequencing Ready Reaction Kit (Perkin-Elmer), with AmpliTaq® DNA 
polymerase FS, following the manufacturer's instruction. The sequencing template was 
100 ng RT-PCR product purified with Microcon® 30 (Amicon) columns. 
Oligonucleotides NFExl6A and NFExl6B were used as extension primers. Reaction 
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products were precipitated in a 70% ethanol/0.5 mM MgCh solution, dried, and 
resuspended in 9 µI of loading buffer (5 volumes of deionized fonnamide, 1 volume of 
25 mM EDT A pH 8, and 50 mg/ml dextran blue ), denatured 2 min at 90°C, and placed on 
ice. A 1.5 µl of each sample was loaded onto a 6% acrylamide-urea gel for 
electrophoresis, using a ABI PRISM® 377 DNA sequencer (Perkin-Elmer), followed by 
analysis with DNA Sequencing Analysis Software. 
2.9 Splicing reaction 
2.9. l ln vivo splicing 
Plasmid DUP4-l, a chimeric j3-globin minigene (Modafferi and Black, 1997; Wei 
et al., 1997), was used for in vivo splicing. The globin sequences were fused to the CMV 
immediately-early promoter. Between exon 1 and exon 3 (from globin), there is a 33-
nucleotide hybrid exon, exon 2. The exon 2 is always spliced out and thus DUP4-l was 
used as control. The NF 1 fragments were cloned at ApaI site ( 4 7 nucleotide upstream 
from exon 2) and BgnI site ( 46 nucleotide downstream from the exon 2) to replace exon 
2 (Fig. 12, also refered to Fig. 22 and Fig. 23). 
Three types of NFI genomic fragments were used: DUPl l-12a, DUP12aL and 
DUP12aS of both the wild type (wt) and mutant (mut). (1) The DUPI l-12a fragment 
(Figure 12) was from digestion of pUC l l- l 2a with Eco RI and BamHI. This EcoRI-
BamHI fragment was transiently cloned into pBluescript II KS(+) to obtain an ApaI site 
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11-F =,---w-n_t_I __, 
pUC18 
PCR * 1 E>an 12a r.: 
~ l:Z..-R 
f Ligation 
1 EcoRJ - OamHI 
11-F t 
EcoRl~---Ex_on_l_I __,1-----11 Exon 12& ÇBamHl 
pBluescript Il KS(-) + Apal - BamHJ 
11-F 
CMV 
Ap:il ~===Ex=un=l=I ===t-----11 E'Uln l:?.i Ç Bamlll 
pBluescript Il KS( t-) 
+ Apal + Bglll 
20S6+1 G-+A 
Extract of R!'1A, RT. and PCR with 
primers GE 1 and GE2. 
Bglll 
Figure 12. Strategy used to clone genomic ll-l2a into pDUP4-1 for cbaracterization of 
mutation 5313. The 11-12a was obtained by digestion of pUCI 1-12a with EcoRI and BamHL 
The EcoRI and BamHl fragment was cloned into pBluescript Il KS(+). The Apal-BamHl fragment 
was then cloned into pDUP4-l. DUPl l-12a was used to transfect HeLa cells. After transient 
expression, RNA was extracted and reverse transcribed. Splicing products were amplified by PCR. 
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at the 5' end. The Apal-BamHI fragment from pBluescript II KS(+) was recloned into 
DUP4-l at Apal and Bglll site. (2) The DUP12aL fragment (550 bp) was obtained by 
digestion of pUCl l-12a with Haelll and BamHI (Figure 13). The Haelll site is at intron 
11 (1934-371, accession number M82814). The BamHI site is a pUC18 site. This Haelll-
BamHl fragment was cloned in DUP4- l at the Apal and Bglll site with Apal site blunted 
with T4 DNA polymerase. (3) The DUP12aS fragment (287 bp) was prepared similarly 
to DUP12L by digestion of pUCl l-12a with Hindlll (at intron 11, 1934-105, accession 
number M82814) and BamHI (Figure 13). The Hindlll site (in NFI fragment) and the 
Apal site (in DUP4-l) were both blunted with T4 DNA polymerase. 
Plasmid DNA was purified by banding in CsCl gradients twice. Lipofectamine 
(GibcoBRL) was used to transfect HeLa cells following the manufacturer's instructions. 
Briefly, 10-20 µg of each plasmid DNA was mixed with 20-50 µlof Lipofectamine and 
incubated in room temperature for 45 min to allow DNA-liposome complexes to form. 
The DNA-liposome complexes were laid onto PBS rinsed cells. Transfection was carried 
out for 24 hr. After removing the DNA-liposome complexes, cells were allowed to 
transiently express for another 24 br. 
Cytoplamic RNA from transfected cells was prepared by TRlzol (GibcoBRL) and 
treated with DNase 1. Reverse transcription was carried out with random hexamer 
primers using l 0 units of AMV reverse transcriptase in 20 µl of total volume containing 
up to 5 µg of total RNA, 10 mM OTT, 1 mM dNTP and 4 u of RNasin (Promega). The 
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Figure 13. Strategy used to clone genomic 12a into pDUP4-1 for characterization of 
mutation 5313. The 12aL was obtained by digestion of pUCI 1-12a with HaeIII and BamHI 
which was then cloned into pDUP4-l. The 12aS was obtained by digestion of pUC 11-12a 
with Hindlll and BamHI and cloned into pDUP4-l. The constructs were used to transfect 
HeLa cells. After transient expression, RNA was extracted and reverse transcribed. Splicing 
products were amplified by PCR with DUP primers GEi and GE2. The parent pDU4-1 was 
used as control. 
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25 µl containing 2.5 µlof cDNA, lx Taq buffer (Amersham), 2 mM dNTP, 5 pmol each 
primers GEl: 5' ACA CAA CTG TGT TCA CTA GC 3' and GE2: 5' AGT GGA CAG 
ATC CCC AAA GG 3 ', 2.5 u Taq polymerase. The amplification was 5 min at 96°C, 35 
cycles of l min at 93°C, 1 min at 55°C, and 1 min at 72°C, and finally 10 min elongation 
at 72°C. PCR products were electrophoresed in 1 % agarose gel and bands were excised. 
DNA were electroeluted, cloned into pUC 18 at the Smal site, and sequenced. 
2.9.2 ln vitro splicing 
The plasmid pSPAd51u1 was described previously (Lavigueur et al., 1993) with the 
Hindlll site at position 225 of the intron modified to a Stul site. A 280 bp fragment was 
prepared by digestion of pUCl l-12a with Hindlll and Hincll, and cloned into pSPAdstul 
at the Stul site (Figure 14). The ends of Hindlll (at intron 11, position 1934-105, 
accession number M82814) and Hincll (a pUC18 site) were both blunted. Splicing 
substrates were produced from plasmids linearized with BamHl and transcripted with 
SP6 RNA polymerase (Pharmacia) in the presence of cap analog and [ a-32P]UTP 
(Amersham) (Figure 15). Transcript RNA purification (Chabot, 1994), HeLa nuclear 
extracts preparation (Dignam et al., 1983) and splicing reaction (Chabot et al., 1997) 
were carried out as described. 
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Figure 14. Strategy used to clone genomic 12a into pSPAd for characterization of 
mutation 5313. The 12a fragment was obtained by digestion ofpUC11-12a with Haelll 
and Hindi. The HaeIII and Hincll sites were blunted and then cloned into pSPAd at the 
Stul site. The construct was linearized with BamHI and used as template for in vitro 
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Figure 15. Schematic diagram of production of pre-mRNA template and the in 
vitro splicing reaction. The exon 12a was cloned into pSPAd and linearized with 
BamHI to give the template DNA. The 'run-off transcription used SP6 RNA 
polymerase. The nascent RNA of the correct size was eut from the gel, extracted, and 
used for in vitro splicing in a HeLa nuclear extract. 
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RNA mobility-shift assays were performed by incubating RNAs for 15 min on ice 
in splicing conditions prior to addition of 1 mg/ml heparin and incubation for 2 min on 
ice. The reaction products were run on a 5% native acrylamide gel, 5% glycerol, 50 mM 
Tris, 50 mM glycine in Tris-glycine running buffer (50 mM Tris, 50 mM glycine). 
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CHAPTER 3 RESULTS AND DISCUSSION 
This chapter is divided into four sections, namely: 
3.1 A nove! mutation in the NFI gene promotes skipping of two exons by affecting 
exon definition ................................................................................................... 58 
3.2 Identification and characterization of six nove! deletions in the NF 1 gene ......... 77 
3.3 A nove! and very peculiar Hincll polymorphism in the 5' region of the human 
Neurofibromatosis type 1 (NF 1) gene ................................................................ 97 
3.4 Linkage disequilibrium analysis between four intragenic polymorphie 
microsatellites of the NFJ gene in the Québec population ................................ 102 
The strategy for the NF 1 mutation study is as outlined in Figure 16. Firstly, the 
segregation of disease-bearing chromosome was analyzed by haplotyping the NFI 
families. Then, the analysis of loss of heterozygosity (LOH) and Southern blotting were 
used to study deletions. Meanwhile, protein truncation test (PTT) was used to detect 
mutations with truncated neurofibromin. A splicing mutation was identified in family 
5313 (Section 3.1 ). Six gross deletions were detected in two families (7610 and 7473) 
and four patients (178, 184, 236 and 237) (Section 3.2). During the screening deletion by 
Southern blotting, a Hincll polymorphism was detected in the 5' region of the NFJ gene 
(Section 3.3). Linkage disequilibrium at the NF 1 locus between four intragenic 
microsatellites was investigated in the Québec population by using the haplotype data 
(Section 3.4). The work was collaborated with Drs. D. Vidaud and Jean-Paul Thirion 
(protein truncation test), and Mr. Martin J. Simard (in vitro splicng). 
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NF l patients ( 19 family 
cases, 20 non-family cases) 
l 
Loss of heterozygosity analysis, 
Southern blotting, Blot 
densitometric analysis 
l 
Protein truncation test 
) 
Haplotype data was used in 
linkage disequilibrium analysis. 
A Hindi polymorphism was 
detected. 
Six deletions were identified. 
Mutations 5313 and 9170 were 
identified. 
l 
Sequencing of cDNA and 
genomic DNA of mutation 5313 
l 
In vivo and in vitro splicing 
analysis of mutation 5313. 
Figure 16. Strategy for identification and cbaracterization of NFJ gene mutations. 
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3.1 A novel mutation in the NFJ gene promotes skipping of two exons by affecting 
exon definition 
3.1.1 Results 
To identify the relative position of the mutation in the NF 1 gene of patients Rou 
5313, Rou 9169 and Rou 9170 (thereafter called 5313, 9169 and 9170 for simplification), 
a protein truncation test was performed using RNAs from these patients and from a 
nom1al individual as wild type control. These RNA samples were reverse transcribed and 
amplified to generate nine nested sets of overlapping cDNA fragments (Fig. 17) (Bahuau 
et al., 1998) which were individually subjected to in vitro transcription and translation. 
On SDS gels there was no significant difference between the translation products 
obtained with patient 53 13 and the control except for the polypeptides generated with 
fragment C (Fig. 17, Fig. 18A). Whereas the control sample yielded a 46 Kd product, 
fragment C from patient 5313 produced both the 46 Kd product and a shorter peptide of 
approximately 42.5 Kd. Because fragment C spans 1459 bp of coding sequences from 
exons 1 Ob to 17, it could theoretically yield a 486 amino acid peptide. The truncated 
polypeptide was estimated to be around 35-50 amino acids shorter than the wild type 
polypeptide. No truncated protein was detected with patients 9169 and 9170 (Fig. 17). 
Similar PTT experiments were carried out with patients 9169 and 9170 by using 
different primers dividing the coding sequence into 5 overlapping segments (Laboratory 
Dr. Kam-Morgan, Laboratory Corporation of America, Research Triangle Park, USA) 
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A. B. C. 
WT 5313 9169 9170 WT 5313 9169 9170 WT 5313 9169 9170 R816X 
I~ 
D. E. 
R816X WT 5313 9169 9170 WT 5313 9169 9170 
~ . '"""'' ' .. ' ·' . ~ 
G. H. 
WT 5313 9169 9170 WT 5313 9169 9170 
F. 
_ 83 Kd 
- 62Kd 




WT 5313 9169 9170 
I. 
WT 5313 9169 9170 
Figure 17. Protein truncation test results. The translation products from fragments A-I 
of the wild type (WT) and patients R816X (control), 5313, 9169 and 9170 were labeled 
with 35S-methionine and fractionated by SDS-PAGE. Molecular weights were indicated 
along fragment C by comparison with colored protein markers. A protein truncation 
mutant R8 l 6X was used as positive control. No difference was observed except for 












Figure 18. Protein truncation and heteroduplex formation assays. (A) Protein truncation assay. 
The translation products from fragment C of the wild type (WT) and mutant (Mut) NFl cDNA were 
labeled with 35s-methionine and fractionated by SDS-PAGE. The size of the wild type and the 
mutant proteins are 46 Kd and 42.5 Kd, respectively. Molecular weights were determined by com-
parison with colored protein markers (B) Gel electrophoresis of the RT-PCR products derived from 
fragment C of patient 5313. The 900 bp and 700 bp fragments correspond to the wild-type and mutat-
ed alleles, respectively, while the 750 bp fragment most probably corresponds to an heteroduplex. 
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(Heim et al., 1995). No truncated polypeptide was detected with patient 9169. With 
patient 9170, an approximate 29 Kd truncated protein was detected in segment 2, which 
encodes into a full length polypeptide product of 78.2 Kd (data not shown). Segment 2 
covers nucleotides 1468 to 3583 of the cDNA sequence, spanning exons lOb to 21 (Heim 
et al., 1995). This suggests that the mutation in patient 9170 is located between 
nucleotide 1468 and 2252, thus between exons lOb and 14. However, no further 
characterization was carried out with mutation 9170. 
To confirm that the NF 1 mutation of patient 5313 was located in cDNA fragment 
C, we monitored heteroduplex formation during PCR amplification of this fragment. 
Figure 188 indicates that in contrast to the wild type sample, patient 5313 yielded two 
bands of almost equal intensities of approximately 900 bp and 700 bp each, as well as a 
third band slightly superior to the 700 bp. This third band most likely represents an 
heteroduplex formed between one wild type and one mutant DNA strand. This result 
suggests that the mutant mRNA lacks approximately 200 nucleotides, a value that would 
correspond to a loss of about 66 amino acids, in agreement with the result of the protein 
truncation assay. 
To identify the mutation, the PCR mixture containing cDNA fragment C from 
patient 5313 was sequenced (Fig. l 9A). The arrow indicates the first position where the 
profile changes from a unique sequence to the superposition of two different sequences. 
Left of the arrow, the sequence AGCAATGGAG corresponds to the 3' end ofwild type 
exon lOc. This sequence continues with a mixture oftwo sequences: GCTCTGCT, which 
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Figure 19. Sequence of the mutated NF 1 allele. (A) Sequence of the fragment C 
portion of the mutated cDNA from patient 5313. Left of the arrow is the normal sequence 
for the 3' end of exon 1 Oc; this followed by the superposition of the sequences 
corresponding to exons 11 and 12b. (8) Genomic sequence of the non-coding strand 
corresponding to the intron l 2a-exon l 2a boundary for the mutant and wild type alleles. 
These sequences differ by a C to T transition at the 5' splice site of intron 12 (position 
2056+1). 
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matches the 5' end of exon 11, and CAGGCAGA, which corresponds to the 5' end of 
exon 12b. This result indicates that the mutated m.RNA produced in patient 5313 lacks 
exons 11 and 12a. Notably, the absence of exons 11 and 12a maintains the proper 
reading frame in the coding sequence of the mutant m.RNA. These observations are 
therefore entirely consistent with the results of the protein truncation test and 
heteroduplex formation assay since the loss of exons 11 and 12a corresponds to 204 
nucleotides in the NFl mRNA and 68 amino acids in neurofibromin. 
T o distinguish between a genomic deletion and a mutation that promo tes aberrant 
pre-mRNA splicing, firstly the patient 5313 family was haplotyped and analyzed for the 
lost of heterozygosity. Figure 20 shows that the mother (1-2) who could be hemizygous 
at the NF/ loci is indeed homozygous by analysis of the segregation of the markers in the 
whole family at these loci. Then, genomic DNA of patient 5313 was digested with 
EcoRI, Mspl, Pstl and Xbal, and submitted to Southern blot analysis with probes 
covering the exons 11 to 12 region. A genomic deletion from exon 11 to exon l 2a would 
remove at least 1.5 kb of DNA. However, no difference was observed between wild type 
and mutant genomic DNA digests (Fig. 21) suggesting that the mutation that led to exon 
skipping cannot be a large deletion. To identify the mutation in the gene, the genomic 
DNA of patient 5313 from intron lOc to intron 12a was amplified by PCR. Ten 
independent clones derived from this region, which should contain either the normal or 
the mutated allele were sequenced. For three clones the sequences corresponded to the 
wild type allele and for seven clones the sequences contained a C to T transition at 
position 2056+ 1 (or a G to A on the coding strand) (Fig. 198). This + 1 position 
63 
1 kb I-1 I-2 II-1 II-2 
I-1 
500 
I-2 J 500 RsaI RFLP 
A C G T I-1 I-2 II-1 II-2 
212 212 1YS26-2.3 
219 215 219 IYS27 AC28.4 
108 106 108 IVS27AC33 .l 
A C G T I-1 I-2 II-1 II-2 
187 185 187 IVS38GT53.0 
A C G T I-1 I-2 II-1 II-2 
II-1 II-2 
500 500 500 500 
212 212 212 212 A C G T I-1 I-2 II-1 II-2 
215 219 215 219 
106 108 106 108 
185 187 185 187 
Figure 20 Pedigree and haplotype of family 5313. Haplotypes were determined by 
analysis of 5 polymorphie loci. Microsatellite fragments and Rsal polymorphism are 
indicated as bp at loci along each chromosome. The NF 1 patient and the mutation-carrying 
chromosome are in black. For the mother, it was not possible to identify the mutation-
carrying chromosome and the chromosomes are in grey. Results are shown on the right. 
64 
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-Exon 11 
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Figure 21. Southern blot analysis of mutation 5313. Genomic DNA of the patient 
53 I3 (Mut) and a control wild-type(WT) were digested with EcoRI , Mspl , Pst! and 
Xbal and sequentially hybridised with probes FFI (1.0 kb) and FFI (43 0 bp). No 
abnormal band in the mutant sample was detected in both hybridizations, indicating no 
deletion in this region. The schematic drawing of the probes FFI (1.0 kb) and FFI 
(430 bp) is shown in the left side. The Southern results with probe FFI (1.0 kb) is 
shown on the right side. 
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corresponds to the first intron nucleotide of the 5' splice site of exon l2a (wild type 
sequence is AAGIGT AAGC, where / is the exon/intron junction and position + 1 is 
indicated in bold and italic). 
Mutations that affect position + l of an intron often promote the use of aberrant 
(cryptic) splice sites or lead to skipping of the exon (Krawczak et al., 1992). To 
investigate the type of splicing anomaly created by the presence of the mutation in the 
NF l intron, we conducted in vivo splicing assays using a 2.2 kb genomic portion 
extending from intron l Oc to intron l 2a. The wild type and mutated l 1- l 2a segments 
were inserted in between the two human ~-globin exons of a reporter construct (DUP4- l) 
(Fig. 22). Following transfection of HeLa cells and transient expression, total RNA was 
isolated. The splicing products were reversed transcribed and amplified by PCR using 
globin-specific primers. T o confirm the identity of these products, DNA bands were 
excised from the gel, cloned and sequenced. Because the small size of exon 2 leads to 
exon 2 skipping (Dominski and Kole, 1991 ), transfection with the parent DUP4-l always 
yielded a 192 bp product corresponding to splicing between exon l and exon 3 (Fig. 238, 
lane 7). The expression vector carrying the wild type l l- l 2a segment yielded products 
containing exon 12a but also a product carrying both exons 11 and 12a (Fig. 238, lane 6). 
Because this latter product was less abundant and because no product containing the NF l 
exon 11 alone was detected, inclusion of exon 11 is less efficient than inclusion of exon 
12a. Comparison of the 3' and 5' splice site sequences TTTTAAAAAATTCAG/ and 
/GT AT AT surrounding exon 11 with respective consensus sequences (Py)nNCAG/ and 




1 1 3 
--+ +--
GEl GE2 
B. 12a in DUP4-1 
1 j 12a j 3 
1 1 3 
C. 11-12a in DUP4-1 
1 
1 
----11 11 3 
1 
Figure 22. Theoretical splicing patterns of constructs with wild type NFJ exons 
11 and 12a in DUP4-1. (A) The parent DUP4-1 always gives exclusion product 
without exon 2. (B) The DUP12L and DUP12S have two possible splicing patterns: 
exon 12a inclusion, exon 12a exclusion. (C) The DUP11-12a has four possible 
splicing patterns: exon 11 and exon 12a both inclusion, exon 12a inclusion, exon 11 
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+ Transfection of Hela cells 
+ Transient expression 
+ Extract of RNA, RT, and PCR with DUP primers GE1 and GE2 
B. 12aS 12aL 11-12a 
Figure 23. In vivo splicing of NFl exons 11 and 12a. (A) Map of the NFI fragments 
and the globin minigene. Three NFI fragments were cloned into the human globin 
reporter gene DUP4-l at the Apal and Bglll sites. The position of the G~A mutation is 
indicated by the arrow. Exons are shown as boxes, the introns as lines. The transcription 
start site in DUP4-l is as indicated by the arrow. The positions of PCR primers GEl and 
GE2 are as indicated. (B) Migration of the RT-PCR products on agarose gels containing 
ethidium bromide after amplification with GE 1 and GE2 primers. The assay was 
performed on total cellular RNA after transient transfection of HeLa cells with the wild-
type (wt) or the mutated (m) versions of each construct. The amplification products were 
electroeluted and sequenced (not shown). The identity of the splicing products as 
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C. Sequences of NF/ splice sites 
3' splice site 
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S' splice site 
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Figure 24. Sequences of splice jonctions in genomic NFJ from exons 10c-12b. 
(A) Exon and intron sizes from intron lOb to intron 12 (not to scale); (B) The 
consensus splice site sequences; and (C) the splice site sequences of exons 11 and 
12a. Because position +5 of the 5' splice site of exon 11 is nota G, this donor site 
is most probably weak. Likewise, the pyrimidine stretches at the 3' splice sites of 
both exons 11 and 12a are interrupted by purines, suggesting weak sites. 
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Notably, expression of the mutated version led to complete skipping ofboth NF/ exons, 
thereby reproducing in HeLa cells the effects observed with patient 5313. The effect of 
the mutation on the inclusion of exon l 2a was confirmed by testing DUP versions 
containing exon l 2a and varying portions of flanking intron sequences (Fig. 23A, 
DUP12aL and DUP12aS). In this case, while wild type DUP12aL and DUP12S both 
yielded a product containing exon 12a (315 bp fragment in Fig. 238, lanes 2 and 4), the 
mutated versions yielded the exclusion products only ( 192 bp fragment in lanes 1 and 3 ). 
This result confirms that the G~A mutation at position + 1 of the 5' splice site of intron 
l 2a prevents the use of exon l 2a. ln addition, the fact that globin exon l is never spliced 
to the mutant NFl exon 12a suggests that the 3' splice site of exon 12a is intrinsically 
weak. 
According to the model of exon definition (Berget, 1995), a mutation in the 
downstream 5' splice site is predicted to reduce the use of the upstream 3' splice site. 
Thus, the G~A mutation at position + l has two consequences: first, it inhibits exon 
12a/12b splicing, an effect common to many mutations that affect 5' splice sites 
(Krawczak et al., 1992); second, it prevents exon definition across exon l 2a, thereby 
compromising the use of the 3' splice site of exon 12a. Because inclusion of exon 11 is 
intrinsically inefficient and may normally rely on the 3' splice site of exon 12a, the 
mutation promotes skipping ofboth exon 11 and exon 12a (Fig. 25). 
To verify whether the 5' splice site of exon 12a is indeed important for the use of 
upstream 3' splice site, we relied on an in vitro splicing assay using a chimeric 
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---t lOc 12a 12b--
lntron 12a 
The + 1 G-7A mutation of exon 
l2a 5' splice site 
-[IQfYT--ttAG [I[}T--ttAGj 12a 1 AT AG [illl-
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------------. -~AGj 12a 1 AT--.AG [illl-
lntron 12a 
j 
lOc 11 12a l 12bl lOc 112bl 
Figure 25. Mutation 20S6+1G~A promotes skipping of exons li and 12a. Exons lOc, 11, 
l2a and 12b are depicted as boxes and introns thin lines. The conserved dinucleotide at splice 
site, 5' GT and 3' AG, are shown. 
71 
adenovirus/Nfl pre-mRNA (Fig. 26A). Following a time-course incubation in a HeLa 
nuclear extract, lariat products diagnostic of splicing were detected with the pre-mRNA 
containing the wild type 5' splice site of exon 12a (Fig. 26A, lanes 1-4). ln contrast, 
splicing products derived from the pre-mRNA carrying the mutated 5' splice site of exon 
12a could not be detected (lanes 5-8). This result demonstrates that an intact 5' splice site 
of exon 12a is essential for the use of the upstream 3' splice site, consistent with the exon 
definition model. As confirmed by native gel analysis, lack of splicing was associated 
with inefficient assembly of splicing complexes on the 3' splice site of exon 12a (fig. 
268). Overall, our results demonstrate that the mutation at the 5' splice site of exon 12a 
inactivates this site and prevents the use of the upstream 3' splice site. Combined with the 
intrinsic weakness of exon 11 splice sites, the G--?A mutation yields mRNAs lacking 
both exons 11 and l 2a. 
3.1.2 Discussion 
lt is estimated that 15% of ail point mutations that cause genetic diseases affects 
pre-mRNA splicing (Krawczak et al., 1992). ln NF l, this proportion bas been reported to 
be even much higher, of the order of 50% (Ars et al., 2000). Among them one finds a 5' 
splice site mutation affecting the invariable GT dinucleotide in intron 16 in two unrelated 
patients (Maynard et al., 1992). Also, a donor splice site mutation in intron 18 was 
reported to result in skipping of NF J exon 18 (Purandare et al., 1995). Three other splice 
site mutations have been found in the region encompassing exons 20 to 27a which 
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Figure 26. The S' splice site of exon 12a plays arole in exon definition. (A) In vitro 
splicing assay. A 32P-labeled adenovirus/NFl chimeric pre-mRNA was incubated in a 
HeLa nuclear extract for the time indicated above the lanes (in hours). Both the wild-type 
and the mutated version carrying the G~A lesion in the 5' splice site of exon 12a were 
tested. Splicing products were fractionated on denaturing acrylamide gel. Only the 
portion of the gel that contains lariat intermediate and product molecules is shown. A 
control reaction containing a mixture of Ad/12a and Ad/12a-m RNAs was set up to rule 
out the presence of a non-specific inhibitor in the Ad/12a-m RNA preparation. The 
identity of band X is unknown but is unrelated to splicing because it is seen at time O. (B) 
Splicing complex formation in a native gel. Splicing reactions were set up with labeled 
pre-mRNAs and aliquots were harvested at different times (indicated in minutes above 
lanes). Fractionation of splicing complexes was accomplished in a non-denaturing 5% 
acrylamide gel. The identity of complex A (which is formed by the binding of U2 to the 
3' splice site region of the pre-mRNA, refer to Fig. 4) was confirmed by performing an 
assay using a HeLa extract where the U2-snRNA was specifically inactivated by 
oligonucleotide-targeted RNAse H degradation. In this case, complex A was not formed 
following incubation with Ad/12a pre-mRNA (not shown). (This gel was done by Mr. 
Martin Simard.) 
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AG dinucleotide at the 3' splice site of exon 22 and exon 23.2 and the 5' splice site of 
exon 23.2 (Upadhyaya et al., 1997). An A~G mutation was reported at intron position 
+4 and was responsible for the skipping of exon 33 (Hutter et al., 1994). 
Mutations that inactivate a splice junction either promote exon skipping or cryptic 
splice site utilization. In some cases, the mutation directly creates a novel splicing signal. 
We have identified a new mutation which affects the invariable GT dinucleotide of the 5' 
splice site of exon 12a. In contrast to known 5' splice site mutations which always 
promote skipping of the exon immediately preceding the lesion, this NF 1 mutation 
promotes skipping of both exons 11 and l 2a, without changing the reading frame or 
reducing the amount of mutant mRNA. We find that this mutation alters the contribution 
that the donor splice site makes toward improving the use of the upstream 3' splice site. 
Thus, while the mutation as expected prevents exon 12a/exon 12b splicing, it also affects 
exon 11/exon 12a splicing. Because sites of exon 11 are intrinsically weak, skipping of 
both exon l l and exon 12a was the ultimate consequence of the G~A point mutation. To 
our knowledge, this is the first report of a point mutation that causes skipping of multiple 
exons and interferes with the process of exon definition. A point mutation that creates a 
novel 5' splice site which leads to the activation of an upstream cryptic 3' splice site was 
described in one thalassemic patient (Treisman et al., 1983). Although this phenotype is 
consistent with the theory of exon definition, this interpretation bas yet to be confirmed. 
The neurofibromin protein is an exceptionally large protein which must probably 
have multiple functions. It bas been reported (Fahsold et al., 2000) that missense or 
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single-amino-acid-deletion mutations are clustered in two distinct regions, the GAP-
related domain and an upstream gene segment comprising exons 11-1 7. The latter region 
encodes a cysteine/serine-rich domain with three cysteine pairs suggestive of ATP 
binding, as well as three potential cAMP-dependent protein kinase (PKA) recognition 
sites. The functional importance of this region encoded by exons 12a, 15 and 16 is 
suggested by its high degree of conservation between human and Drosophila, and by its 
high occurrence of mutations. Our result with mutation 5313 which promotes skipping of 
exons 11 and l 2a also supports the biological relevance of this region for the function of 
neurofibromin. 
NF 1 is notable for its wide range of clinical presentations that may vary from mild 
to severe even within members of the same family. These observations have raised the 
possibility that the expression of disease-causing mutations may be modulated by other 
genetic (Easton et al., 1993) or epigenetic factors (Riccardi, 1993). A statistical analysis 
of the clinical features in a group of NF 1 patients concluded that the observed variability 
was most likely attributable to somatic mutations, modifying gene or genes that modulate 
NFl gene expression (Eisenbarth et al., 2000; Easton et al., 1993). Gene dosage, 
methylation, mRNA editing, and alternative RNA splicing have been proposed to play 
potential roles in the pathogenesis of NFl, and therefore contribute to the variability of 
the clinical manifestations. The neurofibromin protein being an exceptionally large 
protein with most probably multiple fonctions, mutations that affect one or several of 
these functions may contribute to the pleiotropic effects. Current evidence suggests that 
RNA splicing and RNA metabolism play a critical role in the normal control of NFl 
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expression (Skuse and Cappione, 1997). When the splicing profile of the NF l pre-mRNA 
is altered as with patient 5313, truncated forms of neurofibromin may exert dominant 
negative effects that may vary depending on the affected region. Because splicing 
decisions are controlled by a variety of cell-specific, sex-specific and possibly age-
specific factors, it would not be surprising that subtle differences in NFl RNA splicing 
between affected individuals may lead to large differences in the clinicat presentation of 
the NFl disease. 
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3.2 Identification and characterization of six novel deletions in the NFJ gene 
3.2.1 Results 
Besides the identification of mutations by the protein truncation test, deletions 
were searched by loss of heterozygosity analysis and Southern blotting. Six gross 
deletions (Table 7) have therefore been identified and further characterized in order to 
correlate between phenotype and genotype. 
Table 7. Characteristics of the six novel deletions 
Deletions Breakpoint location Deleted regions 
Rou 7610 Between exons 4a and 4b Breakpoint to 3' end of the gene 
Rou 7473 Between exons 5 and 26 5' end of the gene to the breakpoint 
178 Between exons 23-2 and 27b Breakpoint to 3' end of the gene 
184 Between exons 27b and 29 5' end of the gene to the breakpoint 
236 Between exons 14 and 18 Breakpoint to 3' end of the gene 
237 Between exons 38 and 45 5' end of the gene to the breakpoint 
In loss of heterozygosity analysis (Fig. 27), the failure to inherit one parental 
allele usually indicates a deletion which can be verified by Southern blots. With a 
deletion, extra bands are detected in the blots (Figure 28). Segregation analysis of 
haplotypes constructed with two RFLPs (EcoRI and Rsal) and four microsatellites 
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Figure 27. Mechanism of Loss of heterozygosity (LOH) due to deletion. Loss of 
heterozygosity (LOH) is the loss of alleles on one chromosome as detected by 
haplotyping using markers for which an individual is constitutively heterozygous. 
Markers A and B are both heterozygous (AIA2 and 8182). Loss of allele Al, A2, 
B 1 or 82 indicates a deletion. In the figure, allele 82 is lost, indicating a deletion in 
the region. 
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Figure 28. Detection of the deletion breakpoint by Southern blot. Genomic DNA 
digested with restriction enzyme (RE) gives 3 fragments ( l, 2, 3) when there is no 
deletion. When there is a deletion in one allele, a new fragment ( 4) is created, 
suggesting the location of one of the breakpoints for the deletion. Then, sequences 
either downstream (represented in the figure) or upstream of the breakpoint are deleted 
in this allele. 
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hemizygosity in affected individuals of2 unrelated families (families 7610 and 7473) and 
four patients (178, 184, 236 and 237). Tuen, Southern hybridization followed by blot 
densitometric analysis which investigates the copy number of different region of the NF 1 
gene was used to confirm the presumed deletions and to define the extent of the deletions. 
By analysis of the haplotypes and segregation of the family 7610 (Figure 29), 
both the mother (1-1) and the son (11-1) were found to be hemizygous for markers at exon 
5 (RsaI RFLP), introns 26, 27 and 38, however the Eco RI locus was heterozygous. When 
the genomic DNA was digested with HindIII, BamHl, SacI or XbaI, extra bands of about 
18 kb, IO kb, 9.5 kb, 8 kb were detected respectively with GE2-400 bp probe (Figure 
30A). The same extra bands of Hindlll (18 kb) and BamHl (10 kb) were also detected 
with FF13 (876 bp) probes (Figure 308). Probe GE2 (400 bp) covers exons l to 4a 
including the starting codon (ATG) and overlaps with FF13 (876 bp) by 82 bp in exon 4a. 
Probe FF13 (876 bp) covers exons 4a-9. When 95 bp of exon 4b and exons 4c-9 were 
removed from FF13 (876 bp) by digestion with Hinfl (refer to Figure 9, FF13 (625 bp)), 
no abnormal band was detected with the probe FF13 (625 bp). This indicates that the 
breakpoint of the deletion is between exons 4a and 4b. Desitometry analysis indicates 
that the rest of the NF/ gene is in ail probability deleted. In this family, the deletion arose 
from the maternai allele and ail NF 1 gene except exons l to 4b was deleted. 
With family 7473 (Figure 31), markers at introns 26, 27 and 38 of the mother (Il-
l) and the two daughters (111-1 and 111-2) are heterozygous. Examination of the 
segregation of the Rsal locus ( exon 5) indicates that the mother (11-1) is either 
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Figure 29. Pedigree and haplotype of family 7610 . Haplotypes were determined by 
analysis of 6 polymorphie loci. Microsatellite fragments and Rsal polymorphism are 
indicated as bp at loci along each chromosome. EcoRI polymorphism is indicated as 
fragments in kb. The Eco RI polymorphism detects two-allele fragments of 7 .3 kb and 
4.2 kb. The deleted loci are indicated as O. The NFl patient and the mutation-carrying 
chromosome are in black. Results are shown on the right. 81 
NFJ cDNA 
- oE2 covers exons 1-4a 
------FF13 (876 bp) covers exons 4a-9 
FF13 (625 bp) covers 12 bp of exon 4b and exons 4c-9. 
A. GE2-400 bp B. FF13-876 bp 
Bamill HindII.I Sacl Xbal BamHI Hindi HindIII 
l kb WT 7610 WT 7610 WT 7610 WT 7610 l kb WT 7610 WT 7610 WT 7610 
Figure 30. Southern blot analysis of deletion 7610. Genomic DNA of deletion 7610 and 
wild type (WT) was digested with restriction enzymes as indicated and hybridized with 
probes GE2 (400 bp) (A) and FF13 (876 bp) (B). The approximate positions of probes 
GE2 (400 bp), FF13 (876 bp) and FF13 (625 bp) are as depicted above. Vertical lines 
represent EcoRI sites. Extra bands (indicated with arrow haeds) are detected with probe 
GE2 (400 bp) and FF13 (876 bp), but not with probe FF13 (625 bp) (not shown), 
indicating that the breakpoint of deletion 7610 is in between exons 4a and 4b. 
82 
1 kb 1-1 1-2 Il-1 II-2 Ill-1 ITI-2 
l-1 1-2 
7.3 7.3 7.3 7.3 EcoRl RFLP 
500 500 500 500 Rsal RFLP 
210 210 210 206 IVS26-2.3 
1 kb I-1 I-2 II-1 Il-2 Ill-1 Ill-2 
217 2 19 217 2 17 IYS27 AC28.4 " ... . .. ... 
108 108 108 108 !YS27AC33. I ··--~ ·~----l • .fi' 1 _J 1 
187 185 187 187 IVS38GT53 .0 
, .;,,_, ....... . ~ ... 
f//!f!fllliil* ..... '• '. ... . . ~ 
A C G T I-1 1-2 II-1 II-2 III-1 III-2 
II-1 11-2 
7.3 0 4.2 7.3 
500 0 450 500 
206 210 2 12 214 A C G T I-1 1-2 11-1 11-2 III-1 Ill-2 
217 2 17 2 19 219 
108 108 114 108 
187 187 183 187 
A c G T I-1 1-2 11-1 II-2 Ill-1 Ill-2 
IIl-1 lll-2 
4.2 0 4.2 0 
450 0 450 0 
212 210 212 210 
A C G T 1-1 I-2 11-1 II-2 Ill-1 III-2 
219 217 219 217 
11 4 108 11 4 108 
183 187 183 187 
Figure 31. Pedigree and haplotype of family 7473. Haplotypes were determined by 
analysis of 6 polymorphie loci. Microsatellite fragments and Rsal polymorphism are 
indicated as bp at each loci along each chromosome. EcoRI polymorphism was indicated 
as fragments in kb. The EcoRI polymorphism detects two-allele fragments of 7.3 kb and 
4.2 kb . Deletion loci are indicated as O. The NFl patient and the mutation-carrying 
chromosome are in black. Results are shown on ri!!ht. 83 
homozygous or hemizyous because of the presence of 500 bp and the absence of 450 bp 
fragment. Examination of the Rsal locus of the two daughters (III-1 and III-2) indicates 
that the mother is hemizygous, therefore suggesting a deletion at this locus. The deletion 
was confirmed by the analysis of EcoRI RFLP. At the EcoRI loci, the mother (II-1) and 
the two daughters (III-1 and III-2) were apparently homozygous, with the mother 7.3 kb 
and the two daughters 4.2 kb. Segregation analysis indicated that the 4.2 kb fragments of 
the daughters came from their father (II-1). This suggests that the mother and the two 
daughters are hemizygous. This indicates that the deletion covers at least exons 1 to 5, 
most probably begins upstream from the initiation codon (ATG) and ends before exon 26. 
When further characterization of the deletion by southern blotting was carried out, no 
extra band was detected when the genomic DNA of family 7473 was digested with 15 
different restriction enzymes including EcoRI, EcoRV, Hindlll, Pstl, BamHI, Hincll, 
Sacl, San, Smal, Xbal, Bgll, Bg/ll, Ben, MspI, Pvull. Southern blot densitometry results 
indicated that the region covered by GE2 ( 400 bp, exons l-4a) was deleted, however two 
copies were detected by probe FF 13 (876 bp, exons 4a-9) (Figure 32). Therefore, in 
family 7473, the deletion was derived from maternai chromosome and exons 1-5 were 
deleted. The breakpoint of the deletion is located between exons 5 and 26. 
In the four non-family cases, with patient 178, when genomic DNA was digested 
with Eco RI, an extra band of 2.0 kb was detected using probe FB5D-6 l 5 bp ( covering 
exons 23-2 to 27b) (Figure 33), indicating that the breakpoint of the deletion with this 
patient is in between exons 23-2 and 27b. Microsatellite markers at introns 26, 27, and 38 
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Figure 32. Southern blot densitometry results of deletion 7473. The same membrane 
was hybridized sequentially with (A) probe GE2 (400 bp) and (B) FF13 (876 bp). 
Approximate positions of probes related to NF 1 cDNA are depicted at the top. Southern 
blets are in the middle. Bottom table lists out the densitometrical ratio between deletion 
7473 and wild type (WT) of each band. The wild type controls are arbitrarily assigned a 







970 bp 615 bp 590 bp 
EcoRl 
1 kb WT 178 
TGA 
FBSD 
Figure 33. Southern blot analysis of the patient 178. (A) The approximate positions 
of probe FBSD are as depicted. Vertical lines represents EcoRl sites. (B) Genomic 
DNA of 178 was digested with EcoRl and hybridized with FBSD (615 bp). An extra 
band with size of 2.0 kb was detected as indicated by arrow, indicating the breakpoint 
of the deletion is in between exons 23 -2 and 27b. The molecular weight marker 1 kb 




respectively (Figure 34), suggesting that these loci are deleted. Southern blot 
densitometry analysis confirmed that sequences downstream of the breakpoint were 
deleted. 
With patient 184, extra bands of 9 kb, 16 kb and 6 kb were detected with probe 
F85D (590 bp) when genomic DNA was digested with EcoRI, Bglll and Hindlll (Figure 
358), respectively. The same extra bands (9 kb, 16 kb and 6 kb) were detected with probe 
AE25 (Figure 35C). The overlapping region for these two probes is exons 27b to 29. 
Therefore, the breakpoint for deletion 184 was in between exons 27b and 29. 
Hemizygosities were detected with microsatellite markers at introns 26, 27 (Figure 34) 
with fragments of 212 bp, 216 bp and 109 bp at loci IVS26-2.3, IVS27AC28.4 and 
IVS27 AC33. I respectively. The microsatellite marker at intron 38 (IVS38GT53.0) was 
heterozygous with amplified fragments of 186 bp and 188 bp (Figure 34). These suggest 
that the region upstream of exons 27b-29 is deleted. Southern densitometry confirmed 
that the region upstream of exons 27b-29 was deleted. 
For patient 236, extra bands (5.0 kb with EcoRI and 6.2 kb with Sacl) were 
detected with FFI (1.4 kb) (Figure 368), but not with F85D (970 bp) and other probes. 
Probe FF 1 ( 1.4 kb) covers exons 14-21 and probe F85D (970 bp) covers exons 18-21. 
Therefore, the breakpoint of the deletion is located between exons 14 and 18. 
Microsatellite markers at intron 26, 27 and 38 were hemizygous with amplified fragments 
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Figure 34. Results of loss of heterozygosity analysis for non-family cases (178, 
184, 236 and 237) at microsatellite markers IVS26-2.3 (A), IVS27 AC28.4 (B), 
IVS27 AC33.1 (C) and IVS38GT53.0 (D). Hemizygosity was detected at all loci 
except IVS38GT53.0 for patient 184, where heterozygous 186 and 188 bp fragments 
were identified. The sequencing ladder of pUC18 was used as molecular weight 
marker shown on the left of each microsatellite marker. Amplified fragments were 
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970 bp 615 bp 590 bp 
FB5D covers exons 18-29. 
AE25 (2.2 kb) covers exons 29-38 . 
B. 
EcoRI Bg!II HindIII 
1 kb WT 184 WT 184 WT 184 
C. 
EcoRI Bg!II Sad HindIII 
lkb WT 184 WT 184 WT 184 WT 184 
Figure 35. Southern blot analysis of patient 184. The approximate positions of probes 
FB5D and AE25 are as depicted at the top (A). Vertical lines represent EcoRI sites. 
Genomic DNA of 184 was digested with restriction enzymes as indicated and 
sequentially hybridized with probe FB5D (590 bp) (B) and probe AE 25 (C) using the 
same membrane. Extra bands were detected with both probes FB5D (590 bp) and AE 
25, indicating that the breakpoint of the deletion is in between exons 27b and 29. The 
molecular weight marker 1 kb was run along side. The wild types (WT) sample was 
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Figure 36. Southern blot analysis of the patient 236. (A) The approximate 
positions of probes are as depicted. Vertical lines represent EcoRI sites. (B) 
Genomic DNA of 236 was hybridized with probe FFI (1.4 kb) . Restriction 
enzymes used are as indicated. Extra bands were detected with probe FFI (1.4 
kb), but not with probe FB5D (970 bp) , indicating that the breakpoint of the 
deletion 236 is in between exons I4 and I8. The molecular weight marker I kb 
was run along side. The wild types (WT) sample was treated the same as the 
deletions sample. Extra bands are indicated by arrow heads. 
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and IVS38GTS3.0 respectively (Figure 34). This suggests that the region downstream of 
the breakpoint is deleted. 
For patient 237, when genomic DNA was digested with EcoRI and probed with 
P5 (l.15 kb), a smaller fragment (10 kb) was detected concomitant with the absence of 
the wild type 1 S kb fragment (Figure 3 78). The missing of wild type 15 kb fragment 
may suggest there is a homozygote deletion in this region. When genomic DNA of 
patient 237 was digested with XbaI, an extra band with size of 2.0 kb was detected 
(Figure 378). No abnormality was detected with upstream probe AE25 and other probes 
(data not shown). Probe AE25 covers exons 27b-38 and probe P5 (l.15 kb) covers exons 
36-45. This indicated the breakpoint for this deletion was located between exons 38 and 
45. Microsatellite markers at introns 26, 27, and 38 were hemizygous (Figure 34), 
suggesting these regions are deleted. Southern blot densitometry confirmed that upstream 
of exons 38-45 was deleted. 
In summary (Table 7), the deletion in family 7610 arose from the maternai allele 
and ail the NF 1 gene except exons l to 4b was deleted. The deletion 7473 was also 
derived from maternai chromosome and exons l-5 were deleted. The breakpoint of the 
deletion is located in between exons 5 and 26. In the four non-family cases, the 
breakpoint of deletion 178 was located in between exons 23-2 and 27b and the sequences 
downstream of the breakpoint were deleted. For deletion 184, the breakpoint was in 
between exons 27b and 29, and the region upstream of the breakpoint was deleted. With 
deletion 236, the breakpoint was in between exons 14 and 18 and the region downstream 
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A. 
ATG NFJ cDNA TGA 
3' 
AE25 (2.2 kb) covers exons 29-38. 
B. 
Eco RI Xbal 
1 kb WT 237 WT 237 
• . , 
1.15 kb 0.55 kb 
1 1 
P5 covers exons 36-49. 
Figure 37. Southern blot analysis of patient 237. (A) The approximate positions of 
probes AE25 and P5 are as depicted. Vertical lines represent EcoRI sites. (B) Genomic 
DNA of237 was hybridized with probe P5 (1.15 kb) . Notice that the absence ofwild 
type 15 kb fragment in the patient 237 with EcoRI digestion. An extra band was 
detected with Xbal digestion using probe P5 (1.15 kb). No abnormality was detected 
with probe AE25 (not shown), indicating that the breakpoint of the deletion is between 
exons 38 and 45 . Restriction enzymes used are as indicated. The molecular weight 
marker 1 kb was run along side. The wild types (WT) sample was treated the same as 
the deletion sample. Abnormal bands are indicated by arrow heads. 
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of the breakpoint was deleted. The breakpoint of deletion 237 was in between exons 38 
and 45 and the sequences upstream of the breakpoint were deleted. These six gross 
deletions were distributed randomly across the NF 1 gene and no deletion hot spot was 
found. The deletions are unique and different from those reported previously (Upadhyaya 
et al., 1994; Shen et al., 1996; Feldkamp et al., 1998; Carey and Viskochil, 1999). No 
founder effect bas been found in these deletions. 
3.2.2 Discussion 
The approximate distribution of the six deletions on the NF 1 gene is 
schematically presented in Figure 39. The six novel deletions are randomly distributed 
across NF 1 gene and no deletion hot spot exists (Fig. 38). 
Approximately 70% NF 1 mutations are either frameshift or nonsense mutations 
and predicted to produce truncated neurofibromins that are detectable by the recently 
developed NF 1 protein truncation test. However, large gene deletions would escape 
detection by protein truncation test as well as most other PCR based mutation 
identification methods. Loss of heterozygosity analysis (LOH) is an important deletion 
detection technique (Rasmussen et al., 1998). LOH is able to detect deletions 
encompassing even a single marker. 
Loss of heterozygosity is the loss of alleles on one chromosome detected by 
assaying for markers for which an individual is constitutively heterozygous. Four 
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Figure 38. Approximate extension and distribution of 6 NFJ deletions. Dot 
lines indicate the position of the breakpoints. Black lines indicate the deleted 
regions. The NF l gene is depicted at the top. The exons are indicated as boxes 
on the thin horizontal line (representing introns). The diagram is not quite to 
scale. 
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mechanisms have been proposed to explain the loss of alleles on one chromosome: (1) 
mitotic nondisjunction leading to loss of a whole chromosome, (2) reduplication to give 
three copies of one chromosome leading to the loss of another chromosome, (3) mitotic 
recombination leading to the loss of parts of the chromosome that are distal to the 
crossover, and ( 4) de novo interstitial deletion leading to a interstitial deletion (Strachan 
and Read, 1996; Rasmussen et al., 1998). However, LOH depends on the informativeness 
of the marker(s) and needs for parental DNA. Nevertheless, combination of loss of 
heterozygosity analysis, southern blotting and southern blot densitometry analysis can be 
used as a powerful rnethod to detect gross deletions, especially in non-family cases. In 
our study, six novel deletions were detected, including 2 family cases and 4 non-family 
cases. 
Recent study shows that 4-7% of NF 1 patients have large NF 1 gene deletions 
(Lazaro et al., 1996; Ainsworth et al., 1997; Cnossen et al., 1997; Valero et al., 1997). 
However, our results show that the proportion of large deletion is much higher. About 
10.5% of the deletions are family cases and 20% non-family cases. This may indicate that 
considering family or non-family cases separately, the percentage of deletion is different 
from overall deletion percentage. These six deletions are unique and different from those 
reported previously. No founder effect has been found. 
In our study, with family deletions, both large deletions are derived from maternai 
chromosomes. This is in agreement with previous reports that gross deletions are 
predominantly of maternai origin (Rasmussen et al., 1998; Upadhyaya et al., 1995; 
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Upadhyaya et al., 1998; Lazaro et al., 1996; Ainsworth et al., 1997). This may suggest 
that deletions may occur more frequently during oogenesis. lt bas been suggested that 
gross deletions are commonly associated with distinct manifestations such as learning 
disability/mental retardation, dysmorphie features, neurofibroma, and developmental 
delay (Upadhyaya et al, 1998; Upadhyaya et al, 1996; Cnossen et al, 1997; Tonsgard et 
al, 1997; Wu et al, 1997; Leppigetal, 1997; Valeroetal, 1997; Riva et al, 1996; Kayes et 
al, 1994; Kayes et al, 1992). However, large NF 1 deletions might not always associate 
with unusual clinical features (Rasmussen et al, 1998). ln our study, the clinical features 
of deletion 7610 did not show distinct manifestations. No leaming disability/mental 
retardation, dymorphic features and developmental delay have been diagnosed, but 
neurofibroma were found. Our observations are in agreement with the conclusion that 
gross deletions might not always associated with unusual clinical manifestations. 
Unfortunately, the phenotypes for the other deletions were not available. 
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3.3 A novel and very peculiar Hindi polymorphism in the S' region of the human 
Neurofibromatosis type l (NF/) gene (Appendix 1) 
3.3.l Results 
During characterization of the deletions, when genomic DNA was digested with 
Hincll and analyzed by Southern blotting, a Hincll polymorphism was detected in the 5' 
region of the NFJ gene. The probe used was GE2-400 (nucleotides 2 to 401, exons l to 
4a, of the NFJ cDNA) (Marchuk et al., 1991) obtained by digestion with EcoRI and 
SaclI of GE2 (550 bp) cDNA probe (Wallace et al., 1990). Allelic frequencies were 
determined after HincII digestion of the DNA from 67 unrelated persons: 14 NFl 
patients and 53 unaffected individuals from an ethnically diverse population of Quebec. 
About 10-15 µg of Hincll-digested genomic DNA was analyzed by Southern blotting 
with [a-32P]dCTP-labeled GE2 (400 bp) probe (Sambrook et al., 1989). 
Figure 39 shows the Southern blot profiles of the polymorphism. Seven fragments of 
2.2 kb, 2.4 kb, 3.1 kb, 3.3 kb, 4.0 kb, 5.1 kb and 5.6 kb were detected with the GE2 (400 
bp) probe. The 2.2 kb and 5.6 kb fragments were present in all individuals examined. 
The different alleles are Al (3. l and 3.3 kb), A2 (2.4 and 4.0 kb), and A3 (l .3 and 5.1 
kb). The heterozygote forms of the polymorphism are either 3.1 kb and 3.3 kb on one 
chromosome and 2.4 kb and 4.0 kb on the other chromosome (Al-A2) (Fig. 39A, lane 
l; Fig. 398 lane 5) or 3.1 kb and 3.3 kb on one chromosome and l.3 kb and 5.l kb on 
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Figure 39. Hincll polymorphism pattern. (A) Southern blots of different DNAs. Numbers on 
the left indicate the approximate fragment lengths in kb as deterrnined by 1 kb molecular weight 
marker. (B) Schematic drawings representing the possible de visu chromosomal segregation of 
the polymorphism patterns corresponding to A. The polymorphism fragments are indicated in 
kb. The Hincll sites are represented as short horizontal lines. (C) Southern blols of three differ-
ent heterozygotes illustrating the different ratios of the intensity of the allelic band in the order 
of 1 (A2) to 3 (Al) (lane 9), 1 (Al) to 1 (A2) (lane 10) and 3 (A2) to 1 (Al) (lane 11). 
98 
presumed 1.3 kb was not detected. The 1.3 kb may represent a fragment of an intron, 
and therefore would be undetectable with a cDNA probe. The homozygotes are either 
Al-Al (Figure 39A, lane 3; Figure 398, lane 7) or A2-A2 (Figure 39A, lane 4; Figure 
398, lane 8). The presumed heterozygote A2-A3 and homozygote A3-A3 were not 
observed. 
From the Southern blots, the Al-A2, Al-A3, Al-Al and A2-A2 forms were 
identified. The heterozygosity was 0.776 (52 in 67) for Al-A2 and 0.015 (1 in 67) for 
Al-A3. The homozygosity v1as 0.149 (10 in 67) and 0.06 (4 in 67) for Al-Al and A2-A2 
respectively. Thus the allele frequencies are 0.545, 0.448 and 0.007 for Al, A2 and A3 
respectively. The allele frequencies are calculated as in appendix 2. If one locus is 
assumed, the theoretical frequencies given by the Hardy-Weinberg equilibrium law for 
Al-Al, Al-A2 and A2-A2 are 0.297, 0.488 and 0.201 (For the calculation, see Appendix 
2). The theoretical distribution is 19.9, 32.7 and 13.5. lt differs significantly from the 
observed distribution of 10, 52 and 4 (p < 0.001). These results are clearly incompatible. 
They could be the result of a technical error or not a single NF l locus involved. This 
discrepancy can however be explained if one assumes that GE2 ( 400 bp) reveals not one 
but two similar polymorphisms. For example, the subjects with the 3.1 and 3.3 bands may 
be homozygotes at two loci A 1-A l and B 1-B 1. 
This is supported by further examination of the blots and reports in the literature. 
Figure 39C shows the ratios of the intensities of the Al and A2 allelic bands of the blots 
are of the order of l to 3 (lane 9), l to l (lane l 0) or 3 to l (lane 11 ). This suggests 
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strongly the segregation of four copies instead of two of Al and A2. Moreover it has 
been reported that in addition to the NF 1 gene on chromosome 17, there are at least nine 
NF! related loci on chromosomes 2, 12, 14, 15, 20, 21 and 22 (Cummings et al., 1993; 
Purandare et al., 1995a; Wang et al., 2000). These loci have been observed in PCR based 
co-amplification with the NF 1 gene, especially with exons upstream of exon 28. Our 
results agree with these observations. Thus probe GE2-400 most probably detects the 
polymorphism in the NF/ gene and at least in one other related locus. 
As defined by the GE2 (400 bp) probe (Li et al., 1995; Marchuk et al., 1991), this 
Hincll polymorphism is localized in the 5' region of the NF/ gene. lt must be in an intron 
since there is no Hincll site in the cDNA. 
3.3.2 Discussion 
The restriction fragment length polymorphism described here will be a useful 
diagnostic and reseach tool in the analysis ofNFl both in the indirect diagnosis and in the 
detection of deletions. This Hincll polymorphie marker may be especially useful in 
researches on NFJ related loci on chromosomes 2, 12, 14, 15, 20, 21 and 22 (Cummings 
et al., 1993; Purandare et al., l 995a; Wang et al., 2000), as well other potential 
chromosomes. However, the drawback of this HinclI polymorphism is the cumbersome 
Southern blot method which requires relatively large quantity of DNA and has relatively 
low sensitivity. Most polymorphie markers are PCR-based, which facilitates a sensitive 
and rapid approach (Ainsworth and Rodenhiser, 1991). Localization of the Hincll 
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polymorphism should permit to devise a PCR assay which would provide sensitive and 
rapid detection. 
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3.4 Linkage disequilibrium analysis between four intragenic polymorphie 
microsatellites of the NFI gene in the Québec population 
3.4.1 Results 
With the pedigree and haplotype data of the NF l families, statistical analysis was 
performed for linkage and linkage disequilibrium in the Québec population. 
Linkage disequilibrium was investigated using four intragenic microsatellites, at 
introns 26 (IVS26-2.3, Andersen et al., 1993), 27b (IVS27 AC28.4 and IVS27 AC33. l, 
Lazaro et al., 1994) and 38 (IVS38GT53.0, Lazaro et al., 1993). Three of them are CA 
repeats and the IVS26-2.3 is a T AGA!f AGG/T AAGA repeat. These polymorphisms are 
distributed along an approximately 85 kb genomic DNA region of the NF l gene (Li et 
al., 1995). The IVS26-2.3 polymorphism is the most proximal to the 5' end of this set of 
markers. It is located at intron 26 and is approximately 40 kb apart from microsatellites 
at intron 27b. The distance between markers IVS27AC28.4 and IVS27AC33.l is about 5 
kb, and the distance between IVS27AC28.4 and IVS38GT53.0 is 20 kb (Li et al., 1995, 
Valero et al., 1996). 
We haplotyped four microsatellite loci in 19 NFI families from Québec, 82 
individuals and 164 chromosomes (For pedigrees and haplotypes, see Appendix 3). One 
family (family 7610) was found to carry a deletion in these loci in the NF/ gene. Thus, 
one chromosome each from the mother (1-2) and the son (11-2) of this family did not give 
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information. Therefore, 162 chromosomes are informative for the four microsatellites, 
IVS26-2.3, IVS27AC28.4, IVS33.l and IVS38GT53.0. Ali these microsatellite repeats 
revealed length polymorphisms with several alleles and high heterozygosity values 
ranging from 0.58 to 0.62 (Table 8). The allele sizes and frequencies were obtained after 
analyzing 79 unrelated haplotypes and are summarized in Table 8. No significant 
difference was observed on frequencies between NFl-bearing chromosomes and normal 
chromosomes (Table 8). This indicates that the markers and the disease are linked. For 
the haplotype analysis, many NF 1 chromosomes shared the l 08 bp aile le for marker 
IVS27AC33.l with allele frequency near 0.4 (30179 for overall founders, 20/52 for 
normal individuals and 10/27 for NFI patients) (Table 8). 
The result for LO between markers is included in Table 9. Mostly the significance 
of the test is consistent between the Fisher's test and the x.2 test. Since ·l test is valid only 
in the large sample limit, a condition hardly satisfied in our sparse joint count tables, we 
trust the Fisher's test result more. With the exception of between markers IVS26-2.3 and 
IVS27AC33.l, ail other marker pairs show significant LO. This observation is expected 
since our markers are within a single gene, and LO could be observed for markers within 
1 Mb (Peterson et al. 1995). 
A linkage analysis using the program LINKAGE (result file on Appendix 4) 
under a dominant model (penetrance values are P(DD)=P(D+)=0.9, P(++)=0.003) was 
carried out. There are strong linkage signais for ail 4 markers with LOD score of 3.29, 
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Table 8. Alleles sizes, frequency distributions (overall, normal and NFl), and 
estimated betero~gosi!I for each microsatellite 
Microsatellite Alle le Size Alle le Overall Normal NFl Observed 
(b(!) number (tota1=52) (total=27) heteroz~gosit~ 
IVS26-2.3 48/82=0.585 
l 204 l 0.0127 0.0192 0.0000 
2 206 9 0.1139 0.1346 0.0741 
3 208 7 0.0886 0.0962 0.0741 
4 210 20 0.2532 0.2885 0.1852 
5 212 IO 0.1266 0.0962 0.1852 
6 214 5 0.0633 0.0577 0.0741 
7 216 4 0.0506 0.0769 0.0000 
8 218 4 0.0506 0.0385 0.0741 
9 222 Il 0.1392 0.0962 0.2222 
10 226 8 0.1013 0.0962 0.11 ll 
IVS27 AC28.4 49/82=0.598 
l 215 3 0.0380 0.0577 0.0000 
2 217 18 0.2278 0.2692 0.1481 
3 219 24 0.3038 0.3077 0.2963 
4 221 7 0.0886 0.0577 0.1481 
5 223 0.0127 0.0192 0.0000 
6 225 12 0.1519 0.1346 0.1852 
7 227 12 0.1519 0.1346 0.1852 
8 229 2 0.0253 0.0192 0.0370 
9 231 0 0.0000 0.0000 0.0000 
IVS27AC33.l 51182=0.622 
l 104 l 0.0127 0.0192 0.0000 
2 106 16 0.2025 0.1923 0.2222 
3 108 30 0.3797 0.3846 0.3704 
4 110 5 0.0633 0.0385 O.ll ll 
5 112 l 0.0127 0.0192 0.0000 
6 114 8 0.1013 0.1346 0.0370 
7 ll6 18 0.2278 0.2ll5 0.2593 
IVS38GT53.0 51/82=0.622 
171 3 0.0380 0.0577 0.0000 
2 173 7 0.0886 0.0962 0.0741 
3 175 3 0.0380 0.0385 0.0370 
4 177 3 0.0380 0.0385 0.0370 
5 181 10 0.1266 0.1154 0.1481 
6 183 7 0.0886 0.1154 0.0370 
7 185 24 0.3038 0.2500 0.4074 
8 187 17 0.2125 0.2308 0.1852 
9 189 5 0.0633 0.0577 0.0741 
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Table 9. The association between microsatellite markers 
Marker pairs 
IVS26-2.3/IVS27 AC28.4 
IVS26-2.3/IVS27 AC33. l 
IVS26-2.3/IVS38GT53.0 
IVS27 AC28.4/IVS27 AC33. l 
lVS27 AC28.4/IVS38GT53.0 
IVS27 AC33. l/IVS38GT53.0 
*significant 0.01 <p<0.05 
**highly significant 0.001<p<O.O1 
***very highly significant p<0.001 
P-value from a 99% interval of 
















2.97, 3.64 and 2.76 at recombination fraction theta::0.01. Multipoint linkage analysis 
using GENEHUNTER program leads to a LOD score of 4.35. It is interesting to note 
that the 3-generation pedigree #11 contributes 32% of the LOD score; the pedigree #12 
contributes 20% of the LOD score. Five pedigrees out of 18 combinedly contribute 84% 
of the LOD score, whereas eight pedigrees each contributes either nothing or less than 
2% of the LOD score. 
The existence of a founder haplotype is tested by the HAL program (result file on 
Appendix 5). The data does not provide evidence for the existence of such founder 
haplotype. When the founder haplotype is assumed to contain only one marker allele, the 
p-values are between 0.24 and 0.85, depending on the marker allele chosen to be that 
founder haplotype, and depending on the test statistic. If the founder haplotype is 
assumed to contain 2, 3, or 4 markers, the p-value ranges are 0.55 - 0.90, 0.64 - 0.82, and 
0.32 - 0.82. 
U sing the aile le counts from affected and unaffected pedigree founders, the 
DISLAMB program (result file on Appendix 6) in the DISEQ package determines the p-
value under the null hypothesis of no association between the disease and a marker. For 
the chi-square test, the p-values for ail four markers are between 0.42 and 0.79. For the 
likelihood ratio test, the p-values are ail close to 0.5. In other words, there is no 
indication of population association between the disease and any marker in the dataset. 
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Because there is no evidence for association, the multi-point program OISMUL T in the 
OISEQ package was not run. 
The family-based association tests obtained by the GASSOC program (results file 
on Appendix 7) do not show any significant results. The p-values for a generalized TOT 
statistic (GTDT in GASSOC) are 0.16, 0.11, 0.18, 0.61; the p-values for IDT-like test 
under a dominant disease model (GOOM in GASSOC) are 0.18, 0.15, 0.25, 0.60; and 
those for a TOT-like test under a recessive model (GREC in GASSOC) are 0.20, 0.18, 
0.29, 0.31. None of these p-values are significant. The lack of a family-based 
association and the presence of linkage points out that there is a lack of association 
between the disease and the markers. This conclusion is consistent with our population-
based association study. 
3.4.2 Discussion 
The detection of linkage disequilibrium bas been used to identify candidate genes 
or regions and to narrow down the location of disease genes. Recently attention bas 
focused on the use of whole-genome linkage disequilibriurn studies to map comrnon 
disease gene by using single nucleotide polymorphisms (SNPs) (Kruglyak, 1999). 
Both linkage and linkage-disequilibrium (LO) measures a co-segregation between 
a marker and the disease. Linkage analysis examines evidence of co-segregation of a 
rnarker and the disease within the families, while linkage disequilibrium analysis 
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examines association between a marker allele and the disease in the whole population. 
Linkage results from recombination events in the last 2-3 generations. Linkage 
disequilibrium results from ancestral recombination events. Such an association is 
present completely when there is only one or a few disease haplotype at the titne the 
mutation was first created (founder effect), and if the marker is close enough to the 
disease locus. 
In our analysis, we observed a strong linkage between the four microsatellite 
markers and also between the 4 microsatellites markers and the NFl disease (LOD from 
2. 76 to 3.64) (LINKAGE program). This is in agreement with the previous works with 
the AAA T Alu repeats in which five tetra-allelic Alu length polymorphisms were 
observed to lack independence. These five polymorphisms are strongly linked (Messiaen 
et al., 1993). A high degree of linkage disequilibrium was observed among seven 
intragenic RFLPs (Jorde et al., 1993). The linkage between the AAA T Alu repeats with 
microsatellite markers ACl27.2 and IVS38GT53.0 were also observed, but not with 
IVS27 AC28.4 (Valero et al., 1996). This linkage was also confirmed by six 
polymorphism markers, including two exon markers (Purandare et al., 1996). 
Gene mapping studies indicates that strong LD between disease alleles and 
microsatellite marker alleles are at a distance of about 1 Mb (Peterson et al., 1995). At 
the time of the founder mutation, ail polymorphie loci spanning the region will be in 
complete linkage disequilibium because there is exactly one haplotype containing the 
disease gene. So for every maker locus in the haplotype there is a unique allele associated 
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with the disease. However, with subsequent generations this disequilibrium gradually 
dissipates. The pace of the dissipation is a function of the recombination frequency. 
Markers close to the disease gene will manifest higher levels of disequilibrium than those 
further away. Thus linkage disequilibrium depends on two factors: recombination 
frequency and the number of generations since the mutation was introduced into the 
population. This provides the rationale for tracing down the founder. Strong linkage 
disequilibrium suggests a relatively recent origin for the founder mutation (Martin et al., 
2000; Votruba et al., 1998; Jorde et al., 1993). 
In our study, we observed the 108 bp alleles for IVS27AC33.l with a frequency 
near 0.4 (0.37-0.38). However, the allele frequency of IVS27 AC33. l does not appear to 
be differenct between the affected and unaffected individuals, therefore there is no LO 
between this allele and the disease. 
Results from population-based analysis by programs HAL and DISLAMB 
indicate that linkage disequilibrium between a marker and the NF 1 disease is weak (p-
values are all too large to reject the null hypothesis). It suggests that the existence of the 
founder effect is questionable. However, the results are in agreement with the previous 
described using eight RFLPs in the NF 1 region (Jorde et al., 1993). Virtually no linkage 
disequilibrium is observed between NFl and any of the 8 RFLPs. Ali p values for X2 
estimates wre greater than 0.05 (Jorde et al., 1993). 
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The "family-based association" analysis is developed more recently (MacLean et 
al., 2000). However, family-based association is much more reliable than population-
based, because one always have a "case" and a "control" matched. Tbese analysis detect 
linkage when the linkage disequilibrium between the disease and the marker is present. 
We used the family-based association analysis program GASSOC in our study. No 
linkage disequilibrium was observed, in agreement with the results from population-
based association analysis. lt also suggests no founder effect exits at the NF 1 locus in the 
Québec population. 
The failure to detect founder effect in the NF 1 gene in our Québec population 
collection may be due to (1) the high sporadic mutation rate (50% in literature, 21% in 
this study) in the NF 1 locus and (2) the absence of 100% penetrance that is the same 
haplotype presenting in both affected and unaffected individuals. These two factors 
make the founder analysis in NFJ gene delicate. Additionally, in this study from 14 NFl 
disease haplotypes only 4-5 haplotypes clearly showed to be linked to the disease. These 
haplotypes are 210-221-106-183 in pedigree 11(Appendix3) (LOD=l.41), 222-227-106-
185 in pedigree 12 (LOD=0.85), 212-219-106-185 in pedigree 19 (LOD=0.56), 208-221-
116-175 in pedigree 7 (LOD=0.52) and perhaps 210-217-108-187 in pedigree 16 
(LOD=0.30). This data set is too small to clearly infer the existence of a founder. 
Because Québec is a young isolated population, the founder events would be 
necessarily much more recent (Martin et al., 2000). This should give strong linkage 
disequilibrium score. In addition, the microsatellite markers used in our analysis are very 
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close (0.085 cM) and not easy for crossover events to break the founder haplotype. 
However, our results do not support the existence of linkage disequilibrium in the Québec 
population. In most cases, the key problem in any population-based linkage 
disequilibrium study is the poorly characterized population. Our results suggest that we 
may not be able to consider the Québec population as an isolated population anymore due 
to the rapid and recent mixture with other ethnie immigrants. 
No founder haplotype exists in the Québec population. It may suggest that the 
NFI mutations does not corne from France, but instead originate from the sporadic new 
mutations in Québec. 
111 
CHAPTER 4 CONCLUSION 
Four parts of work have been achieved in this study. They are ( 1) a splice site 
mutation bas been identified and characterized, (2) six deletions have been identified and 
characterized, (3) a HincII polymorphism bas been detected at the 5' region of the NFI 
gene, and (4) linkage disequilibrium ofNFI has analyzed in the Québec population. 
Neurofibromatosis type 1 is one of the most common hereditary disorders 
affecting the human nervous system and characterized with variable clinical 
presentations. Since the cloning of the NF 1 gene in 1990, a great deal has been leamed 
about the genetics and biology of this disorder. NF l bas been elevated to a model status 
(Seizinger, 1993; Carey and Viskochil, 1999) 
In this study, from the nineteen Québec NFl families, one family (5313) has been 
found to carry a splicing mutation and two families (7610 and 7473) have deletions. 
From twenty non-family NFl patients, four patients found to carry deletions. This 
confirms that the mutation rate is high in the NF 1 gene. The mutations are unique and 
different from those reported previously. As expected for a disease with so high mutation 
rate, no linkage disequilibrium and founder effect exist in this Québec population 
collection. The splicing mutation study suggests that the 11-12a region of NF 1 plays an 
important role in the activity of neurofibromin. 
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This study first time showed the splicing mechanism of a spiicing mutation. The 
mutation exerts its effect on splicing process by preventing efficient assembly of complex 
A across the exon. 
The two family deletions both arise from maternai alleles and are not associated 
with unusual clinical features. The six deletions are distributed randomly across NF 1 
gene. This suggests that there is no deletion hot spot in the gene. 
This study points out the importance to study mutations at genomic, RNA and 
protein levels. Special attention should be paid to the aberrations at RNA and protein 
level, which could be different to that predicted solely at the genomic level. lt is 
reasonable to hypothesize that variations in the RNA splicing mechanism may lead to 
different levels of the aberrantly spliced mRNA. Splicing mutations could account for 
part of the clinicat variability that is observed in NF 1 patients carrying the same 
mutation. 
The study proves that the analysis of NF 1 mutation to be complex. But the 
accumulation of mutational data could reveal functional domain, genotype-phenotype 
correlation, and eventually tumorigenic mechanisms in the NFI disorder. 
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novel and very peculiar Hindi polymorphism in the s· region 
of the human neurotibromatosis type 1 CNFI) gene. 
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SUMMARY: We report a Hindi polymorphism in 
the 5' end of the neurofibromatosis type l gene (NFI) 
as detected with a probe made of exons l to 4a 
(nucleotides 2 to 401 of the cDNA). This Hindi site 
is most probably in an intron. Evidence presented 
suggests the probe reveals not one but two similar 
polymorphisms. 
KEY-WORDS: Neurotibromatosis type 1. - Polymorphism. -
NF!. - Human genome - Hindi restriction site. 
Neurofibromatosis type l (NF l ), an autosomal 
dominant disorder, affects about l in 3 500 indivi-
duals and is characterised by multiple neurofibro-
mas, café-au-lait spots, axillary freckling and Lisch 
iris nodules [I, 2]. lt results from the mutation of the 
NF 1 gene located at l 7q 11.2, spanning 350 kb with 
60 exons [3-7]. Southern blotting to screen for dele-
tions indicated a Hindi polymorphism in the 5' 
region of the gene. The probe used was GE2-400 
(nucleotides 2 to 401, exons l to 4a, of the NF 1 
cDNA) [5] obtained by digestion with EcoRI and 
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RÉSUMÉ: Un polymorphisme Hindi. situé en 
position 5' du gène NFI de la neurofibromatose de 
type 1 a été mis en évidence. Il a été détecté grâce à 
une sonde faite des exons 1 à 4a (nucléotides 2 à 
401 du cDNA). Ce site est fort probablement dans 
un intron. Nos résultats suggèrent aussi que la sonde 
révèle non pas un mais deux polymorphismes simi-
laires. 
MOTS-CLÉS: Neurofibromatosc de type 1. - Polymorphisme. 
- NF 1. - Génome humain - Site de restriction Hincl 1. 
Sadi of GE2-550bp cDNA probe [8]. Allelic fre-
quencies were determined after Hindi digestion of 
the DNA from 67 unrelated persons: 14 NFI 
patients and 53 unaffected individuals from an eth-
nically diverse population of Québec. Genomic 
DNA was extracted either from mononuclear cells 
isolated from whole blood by ficoll-hypaque gra-
dient centrifugation or from lymphoblastoid cell 
lines. About 10-15 µg of genomic DNA was analy-
zed by Southern blotting [9]. Briefly, Hincll-diges-
ted genomic DNA was separated by gel electropho-
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a. b. c. 
3.1 2.4 3.1 3.1 3.1 2. 
1.3 
Al-A2 Al-A3 Al-Al A2-A2 
1 2 3 4 5 6 7 8 9 IO 11 
Fig. 1. - Hincll polymorphism pattern. 
a) Southern blots of different DNAs. Numbers on the left indicate the approximate fragment lengths in kb as determined by 
1 kb molecular weight marker. 
b) Schematic drawings representing the possible de visu chromosomal segregation of the polymorphism patterns corres-
ponding to Fig. 1a. The polymorphism fragments are indicated in kb. The Hincll sites are represented as short horizontal 
lines. 
c) Southern blots of three different heterozygotes illustrating the different ratios of the intensity of the allelic band in the 
order of 1 (A2) to 3 (A1) (fane 9), 1 (A1) to 1 (A2) (lane 10) and 3 (A2) to 1 (A1) (lane 11). 
resis and alkali transferred to a Hybon ™-N+ nylon 
membrane (Amershan). Membranes were prehybri-
dized for at least 6 hours at 65°C in a solution com-
posed of 5 x SSC, 5 x Denhardt's solution, 0.5 % 
SOS and 20 µg/ ml of denatured salmon sperm 
DNA. Hybridization was carried out overnight at 
65°C in the same solution, with denatured [a-32p] 
dCTP-labeled GE2-400 probe. Membranes were 
washed first with 2 x SSC at room temperature 
for 20 mins, then with a solution of 0.1 x SSC and 
0.1 % SOS at 65°C for 30 mins. Autoradiography 
was carried out at -70°C using double intensifying 
screens. 
Figure 1 shows the Southern blot profiles of the 
polymorphism. Seven fragments of 2.2 kb, 2.4 kb, 
3.1 kb, 3.3 kb, 4.0 kb, 5.1 kb and 5.6 kb were detec-
ted with the GE2-400 probe. The 2.2 kb and 5.6 kb 
fragments were present in ail individuals examined. 
The different alleles are A 1 (3.1 and 3.3 kb), A2 
(2.4 and 4.0 kb), and A3 (1.3 and 5.1 kb). The hete-
rozygote forms of the polymorphism are either 3.1 
kb and 3.3 kb on one chromosome and 2.4 kb and 
4.0 kb on the other chromosome (A l-A2) (fig. 1 a, 
lane 1 ; fig. 1 b lane 5) or 3.1 kb and 3.3 kb on 
one chromosome and 1.3 kb and 5.1 kb on the 
other chromosome (A l-A3) (fig. la, lane 2; fig. 1 b, 
lane 6) . However, the presumed 1.3 kb was not 
detected. The 1.3 kb may represent a fragment of an 
intron, and therefore would be undetectable with 
a cDNA probe. The homozygote forms are ei ther 
A 1-A 1 (fig. 1 a, la ne 3; fig . 1 b, lane 7) or A2-A2 
(fig. 1 a, lane 4 ; fig . 1 b lane 8). The presumed 
heterozygote form A2-A3 and homozygote form 
A3-A3 were not observed. 
From the Southern blots, Al -A2, A l-A3 , A 1-A 1 
and 4 A2-A2 were identified. The heterozygosity 
was O. 776 (52 in 67) for Al -A2 and 0.015 
(! in 67) for Al-A3. The homozygosity was 0.149 
(10 in 67) and 0.06 (4 in 67) for Al-Al and A2-A2 
respectively. Thus the allele frequencies are 0.545, 
0.448 and 0.007 for A 1, A2 and A3 respectively. If 
one locus is assumed, the theoretical frequencies 
given by the Hardy-Weinberg equilibrium law for 
Al-Al, Al-A2 and A2-A2 are 0.297, 0.488 and 
0.201. The theoretical distribution is 19.9, 32. 7 and 
13.5 . lt differs significantly from the observed 
distribution of 10, 52 and 4 (p < 0.001 ). These 
results are clearly incompatible. They can however 
be explained if one assumes that GE2-400 reveals 
not one but at least two similar polymorphisms. For 
example, the subjects with the 3.1 and 3.3 bands 
may be homozygotes at two loci A 1-A 1 and B 1-B 1. 
This is supported by reports in the literature and 
further examination of the blots. Figure 1 c shows 
the ratio of the intensities of the A 1 and A2 allelic 
bands of the blots are of the order of 1 to 3 (lane 9), 
1 to 1 (Jane 10) or 3 to 1 (lane 1 1 ). This suggests 
strongly the segregation of four copies instead of 
two of A 1 and A2 . lndeed it has been reported that 
in addi tion to the NF/ gene on chromosome 17, 
there are at least ni ne NF 1 related loci on chromo-
somes 2, 12, 14, 15, 20, 21 and 22 (IO, 11] . These 
loci have been observed in PCR based co-amplifi-
cation with the NF 1 gene, especially with exons 
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upstream of exon 28. Our results agree with these 
observations. Thus probe GE2-400 most probably 
detects the polymorphism in NF/ gene and at least 
in one other related locus. 
As defined by the GE2-400 probe (4, 5). This 
Hindi polymorphism is localized in the 5' region of 
the NF I gene. lt must be in an intron since there is 
no Hindi site in the cDNA. 
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Appendix2 
Caculation of allele frequency for Hincll polymorphism 
In 67 individuals, IO Al-Al, 52 Al-A2, 1 Al-A3 and 4 A2-A2 were observed. Therefore 
the frequency of 
Al p = (10 + 52/2 + l/2)/67 = 0.545 
A2 q = ( 4 + 52/2)/67 = 0.448 
A3 = (0 + l/2)/67 = 0.0007 
Theoretical frequencies according to Hardy-Weinberg should be 
p2 = 0.545 X 0.545 = 0.297 
q2 = 0.448 X 0.448 = 0.20 
2pg = 2 X 0.545 X 0.448 = 0.488 
The theoretical distribution is 
Al-Al = 67 x p2 = 19.9 (:;t IO) 
A2-A2 = 67 x q2 = 13.5 (:;t 4) 
Al-A2 = 67 x 2pq = 32.7 (:~ 52) 
Therefore, it differs significantly from the observed distribution. 
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Appendix 3 




Normal male individual, wild type 
Nomal female individual, wild type 
Male F 1 patient 
Female NFl patient 
Normal chromosome, non-NFl chromosome 
Affected chromosome, NF 1-bearing chromosome 
Affection statue unknown, unable to decide the affecting statue 
*The alleles are indicated by bp along each locus. The size (bp) of the allele 













































































































































































































































































































































17 IVS27 AC28.4 
11 6 IVS27AC33.l 












206 210 2 10 210 1VS26-2.3 
2 17 2 19 219 219 IVS27 AC28.4 
11 6 106 106 106 IVS27AC33.l 
17 1 181 181 181 1VS38GT53.0 
II-1 II-2 
206 210 2 10 210 IVS26-2.3 
217 219 2 19 219 IYS27AC28.4 
116 106 106 106 IYS27AC33. l 
171 181 181 181 IVS38GT53.0 
Family 10 
I-1 I-2 
210 2 14 210 210 IVS26-2 .3 
2 17 221 217 219 IVS27 AC28.4 
116 110 116 110 IVS27 AC33. l 
173 187 173 187 IVS38GT53.0 
II-1 
210 210 IVS26-2.3 
217 2 17 IVS27 AC28.4 
116 116 fVS27 AC33 .1 
173 173 IVS38GT53.0 
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II-1 



























218 ~ 219 
108 
187 
2 10 ~ 2 1 
106 
183 





































~ 225 108 187 
II-2 
















226 ~ ~ 222 229 225 




rYS27 AC33 .1 
fVS38GT53.0 
II-4 
210 ~ ~ 210 
fVS26-2.3 
217 217 IVS27 AC28.4 
116 116 rYS27 AC33. I 
173 173 IVS38GT53.0 
III-4 
210 
~W'o 22 1 2 17 106 116 
183 173 
II-4 














































~ 1 21 8 227 25 108 116 185 185 















IVS27 AC33 .1 
IVS38GT53.0 
II-2 
2 18 IVS26-2.3 
225 IVS27 AC28.4 

































Family 16 Family 7473 
1-2 
~ 210 210 ~ ~206 9 217 217
108 108 108 
185 187 187 
11-1 
206 210 212 
217 217 219 
108 108 114 
187 187 183 
111-1 
212 210 212 
219 217 219 
114 108 114 






































































































IVS27 AC33 . l 
IVS38GT53.0 
I-2 





222 IVS26-2 .3 
225 IVS27 AC28.4 






1 ~ 212 216 ~ ~216 
IVS26-2.3 
219 9 9 9 IVS27 AC28.4 
106 116 104 108 IVS27AC33 .l 
185 183 185 185 IVS38GT53.0 
II-1 II-2 
212 216 212 216 IVS26-2.3 
219 219 219 219 IVS27AC28.4 
106 108 106 106 IVS27AC33.l 
185 185 185 183 IVS38GT53 .0 
III-1 III-2 
212 212 216 216 IVS26-2.3 
219 219 219 219 IVS27 AC28.4 
106 106 106 108 IVS27AC33.1 
185 185 183 185 IVS38GT53.0 
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Appendix 4 
Result fde of LINKAGE program 
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LOD TABLE REPORT 
loglO(likelihood at theta/likelihood at theta=0.5) 
Order 0.005 0.01 0.05 0.1 0.2 0.3 0.4 - ----------------
ml 3.29 3.29 3.13 2.82 2.09 l.30 0.57 
l -0.65 -0.65 -0.46 -0.32 -0.15 -0.06 -0.01 
2 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 
4 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
5 0 0 0 0 0 0 0 
7 0.50 0.50 0.45 0.39 026 0.14 0.04 
8 0.10 0.10 0.09 0.07 0.04 0.02 0 
9 0 0 0 0 0 0 0 
10 0 0 0 0 0 0 0 
Il 1.39 1.39 l.28 1.15 0.88 0.60 0.30 
12 0.58 0.58 0.53 0.46 0.31 0.17 0.05 
13 0 0 0 0 0 0 0 
14 0.25 0.25 0.22 0.18 0.11 0.05 0.01 
15 0 0 0 1) 0 0 0 
16 0.29 0.29 0.25 0.21 0.13 0.06 0.02 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0.55 0.55 0.52 0.47 0.38 0.27 0.14 
m2 2.97 2.97 2.72 2.40 1.73 1.06 0.44 
1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 
7 0.50 0.50 0.45 0.39 0.26 0.14 0.04 
8 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 
10 0 0 0 0 0 0 0 
Il 1.39 l.39 l.28 1.15 0.88 0.60 0.30 
12 0.83 0.83 0.76 0.67 0.48 0.27 0.08 
13 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 
15 0.25 0.25 0.22 0.18 0.11 0.05 0.01 
16 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0 0 0 0 0 0 0 
m3 3.64 3.64 3.32 2.91 2.09 l.29 0.56 
1 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 
4 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
5 0 0 0 0 0 0 0 
7 0.50 0.50 0.45 0.39 0.26 0.14 0.04 
8 0.05 0.05 0.05 0.04 0.02 0.01 0 
9 0 0 0 0 0 0 0 
10 0 0 0 0 0 0 0 
150 
11 1.39 1.39 1.28 1.15 0.88 0.60 0.30 
12 0.54 0.54 0.49 0.42 0.28 0.15 0.04 
13 0 0 0 0 0 0 0 
14 0.08 0.08 0.07 0.05 0.03 0.01 0 
15 0.25 0.25 0.22 0.18 0.11 0.05 0.01 
16 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0.55 0.55 0.52 0.47 0.38 0.27 0.14 
m4 2.76 2.76 2.50 2.18 1.53 0.92 0.39 
1 0 0 0 0 0 0 0 
2 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
3 0 0 0 0 0 0 0 
4 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
5 0 0 0 0 0 0 0 
7 0.50 0.50 0.45 0.39 0.26 0.14 0.04 
8 0.05 0.05 0.05 0.04 0.02 0.01 0 
9 0 0 0 0 0 0 0 
IO 0 0 0 0 0 0 0 
11 1.39 1.39 1.28 1.15 0.88 0.60 0.30 
12 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 
15 0.25 0.25 0.22 0.18 0.11 0.05 0.01 
16 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0 0 0 0 0 0 0 
1=5 2.76 2.76 2.50 2.18 1.53 0.92 0.39 
l 0 0 0 0 0 0 0 
2 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
3 0 0 0 0 0 0 0 
4 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
5 0 0 0 0 0 0 0 
7 0.50 0.50 0.45 0.39 0.26 0.14 0.04 
8 0.05 0.05 0.05 0.04 0.02 0.01 0 
9 0 0 0 0 0 0 0 
IO 0 0 0 0 0 0 0 
11 1.39 1.39 1.28 1.15 0.88 0.60 0.30 
12 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 
15 0.25 0.25 0.22 0.18 0.11 0.05 0.01 
16 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0 0 0 0 0 0 0 
!=5 2.76 2.76 2.50 2.18 1.53 0.92 0.39 
1 0 0 0 0 0 0 0 
2 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
3 0 0 0 0 0 0 0 
4 0.28 0.28 0.25 0.21 0.13 0.06 0.02 
5 0 0 0 0 0 0 0 
151 
7 0.50 0.50 0.45 0.39 026 0.14 0.04 
8 0.05 0.05 0.05 0.04 0.02 0.01 0 
9 0 0 0 0 0 0 0 
10 0 0 0 0 0 0 0 
li l.39 l.39 l.28 1.15 0.88 0.60 0.30 
12 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 
15 0.25 0.25 0.22 0.18 0.11 0.05 0.01 
16 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 
19 0 0 0 0 0 0 0 
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Appendix5 
Result fde of HAL program 
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# File: results.out 
# Created on Fri Mar 24 15:20:45 2000 
>>> Welcome to HAL version 1.1: <<< 
>>> Software for linkage disequilibrium mapping of <<< 
>>> complex traits using ancestral haplotypes. <<< 
»> Written by Rory Martin & Charles MacLean. 20 May 1999 «< 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 1 l 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 




Allele freqs . l l 
(cM) Max #Trans to 
(cM) Min Span span atîecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 










80 80 16 
--locally-admiss-- ---t+c---
test control t+c min mean max min mean max 
64 80 80 8.00E+O 1 80 80 8.00E+O 1 80 
S_reg: analytical significance oft-value = 3.2059E-OI 
permutation significance level = 3.1600E-OI 
regression coefficient= l. l 812E-O 1 
std errer of coefficient = 2.5346E-O 1 
regression constant = 1.8047E-O1 
std errer of constant = 4.2507E-02 
t-value for regression coefficient= 4.6604E-OI 
S_est: permutation significance level = 6.1200E-OI 
anc hap stat: raw, normed = 8.4579E-02, -5.2506E-O 1 
replicate samples: mean, std dev = 5.5106E-Ol, 8.8844E-OI 
S_trim: permutation significance level = 3.7700E-Ol 
anc hap stat: raw, normed = -2. 7581 E-0 l, 4.6694E-O 1 
replicate samples: mean, std dev = -9.2696E-Ol, l.3945E+OO 
ovlap -#haps- -#peds- ---- prob _() ----
share th rh t c t c trim t c p_t_hs2 
0.5 1 0 2 7 2 6 9.6E-OI l.2E-OI l.IE-01 2.8E-Ol 
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0.0 0 0 14 57 12 18 4.JE-02 8.8E-Ol 8.9E-Ol 7.2E-Ol 
Haplotype-wise analysis: number offeasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 1 2 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 




Allele freqs .25 
(cM) Max #Trans to 
2 
2 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test contrai mutation alpha 
2.SOOOOE-02 l.OOE-01 O.OOE+OO 8.00E+OO 
2.00E-01 
2 
Number of replicates (feas/ total) = 1000 I l 000 
Founder haplotypes: 
---permutation replicates---
200 l .OOE+OO 
-admissible- --locally-admiss-- ---t+c---
somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+Ol 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 3.5801 E-01 
permutation significance level = 3.6400E-Ol 
regression coefficient= 6. 73 l 9E-02 
std error of coefficient = l .8506E-O l 
regression constant= 1. 7870E-O 1 
std error of constant= 4.6264E-02 
t-value for regression coefficient= 3.6378E-O 1 
S_est: permutation significance level = 8.3600E-Ol 
anc hap stat: raw, normed = O.OOOOE+OO, -5.8570E-O 1 
replicate samples: mean, std dev = 4.8958E-Ol, 8.3589E-Ol 
S_trim: permutation significance level = 5.2500E-Ol 
anc hap stat: raw, normed = -5.4286E-Ol, -l.0257E-Ol 
replicate samples: mean, std dev = -4.34lOE-Ol, l.0604E+OO 
ovlap -#haps- -#peds- ---- prob _() ----
share lh rh t c t c trim t c p_t_hs2 
0.5 1 0 4 16 4 8 9.6E-Ol 2.SE-01 2.5E-01 3.9E-Ol 
0.0 0 0 12 48 l l 18 3.6E-02 7.5E-Ol 7.5E-Ol 6.IE-0! 
Haplotype-wise analysis: number of feasible configurations for: 
155 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 1 3 
Current disease position: 3 
Current ancestral loci: 3 
marker loci (X=Disease, "="=fixed) 




Allele freqs .12 
(cM) Max #Trans to 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
2.50000E-02 l.OOE-01 O.OOE+OO 8.00E+oO 
2.00E-01 
2 






80 80 16 
-locally-admiss- --t+c--
test control t+c min mean max min mean max 
64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 4.8973E-OI 
permutation significance level = 5.0000E-01 
regression coefficient = 6.2444E-03 
std error of coefficient = 2.4250E-O 1 
regression constant= l.8673E-OI 
std error of constant= 4.2869E-02 
t-value for regression coefficient= 2.5750E-02 
S _est: permutation significance level = 9. 7600E-O l 
anc hap stat: raw, normed = -4.6157E-01, -1.1482E+OO 
replicate samples: mean, std dev = 5.4462E-OI, 8.7634E-OI 
S_trim: permutation significance level = 4.8100E-OI 
anc hap stat: raw, normed = -1.3673E+OO, -4.3284E-OI 
replicate samples: mean, std dev = -7.7096E-01, l.3777E+OO 
ovlap -#haps- -#peds- ---- prob _() ----
share lh rh t c t c trim t c p_t_hs2 
0.5 1 0 3 7 3 4 9.6E-OI l.9E-OI l.IE-01 2.SE-01 
0.0 0 0 13 57 11 17 4.3E-02 8.IE-01 8.9E-Ol 7.2E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 1 4 
Current disease position: 4 
Current ancestral loci: 4 
marker loci (X=Disease, "="=fixed) 
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Allele freqs .14 
(cM) Max #Transto 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
2.SOOOOE-02 l .OOE-01 O.OOE+OO 8.00E+oO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 2.5294E-OI 
permutation significance level = 2.4900E-O 1 
regression coefficient = l .4900E-O 1 
std error of coefficient = 2.2397E-O 1 
regression constant= l.7594E-OI 
std error of constant= 4.3372E-02 
t-value for regression coefficient = 6.6526E-O 1 
S est: permutation significance level = 2.9400E-O 1 
anc hap stat: raw, normed = 3.6023E-OI, -l.5705E-OI 
replicate samples: mean, std dev = 4.8592E-OI, 8.0036E-OI 
S _ trim: permutation significance level = l .6700E-O 1 
anc hap stat: raw, normed = 4.2324E-Ol, 9.5178E-Ol 
replicate samples: mean, std dev = -7.5381E-OI, l.2367E+OO 
ovlap -#haps- -#peds- --- prob_() ----
share th rh t c t c trim t c p_t_hs2 
0.5 1 0 3 9 3 6 9.6E-OI l.9E-OI l.4E-Ol 3.0E-01 
0.0 0 0 13 55 11 18 4.2E-02 8.lE-01 8.6E-OI 7.0E-01 
Haplotype-wise analysis: number offeasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 2 5 
Current disease position: 2 5 
Current ancestral loci: 1 
marker loci (X=Disease, "="=fixed} 




Allele freqs .22 
157 
(cM) Max #Trans to 




allele of anc of anc (min) (max) since anc 
freq loci loci test control mutation alpha 
2.50000E-02 l .OOE-01 O.OOE+oO 8.00E+oO 
2.00E-01 
2 





somewhere local test contrai t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 22007E-OI 
permutation significance level = 2.0300E-O 1 
regression coefficient = l .5077E-O 1 
std error of coefficient = 1.9531E-01 
regression constant= l.71 IOE-01 
std error of constant = 4.50 l 6E-02 
t-value for regression coefficient = 7. 7l95E-O1 
S_est: permutation significance level = 3.8500E-OI 
anc hap stat: raw, normed = 3.3483E-OI, -2.0648E-OI 
replicate samples: mean, std dev = 5.2557E-OI, 9.2372E-OI 
S_trim: permutation significance level = 2.1500E-OI 
anc hap stat: raw, normed = 5. l 3l2E-O1, 9 .2321 E-01 
replicate samples: mean, std dev = -5.6656E-01, 1.1695E+OO 
ovlap -#haps- -#peds- ---- prob _() -----
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 4 13 4 7 9.6E-OI 2.SE-01 2.0E-01 3.5E-OI 
0.0 0 0 12 51 11 17 3.8E-02 7.5E-OI 8.0E-01 6.5E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 2 6 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 








( cM) Max # Trans to 
2 6 
2 
(cM) Min Span span affecteds: #Gens 
Disease allele ofanc ofanc (min) (max) since anc 
position freq loci loci test control mutation alpha 
gamma 
158 
2.SOOOOE-02 l .OOE-01 O.OOE+oO 8.00E+OO 2 
2.00E-01 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+ol 80 80 8.00E+ol 80 
S_reg: analytical significance oft-value = 7.8702E-OI 
pennutation significance level = 7.9800E-OI 
regression coefficient = -1.4050E-O 1 
std error of coefficient = 1. 7648E-O 1 
regression constant = 2.0732E-O 1 
std error of constant= 4.73 ISE-02 
t-value for regression coefficient= -7.9613E-OI 
S_est: permutation significance level = 8.SOOOE-02 
anc hap stat: raw, nonned = l.9187E+OO, l.6816E+OO 
replicate samples: mean, std dev = 5.0555E-OI, 8.4035E-OI 
S_trim: pennutation signiticance level = 9.5500E-OI 
anc hap stat: raw, nonned = -l.9716E+OO, -I.5830E+OO 
replicate samples: mean, std dev = -3.5l77E-O1, l.0233E+OO 
ovlap -#haps- -#peds- ------ prob _() ----
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 2 21 2 8 9.7E-Ol l.2E-01 3.3E-OI 4.6E-OI 
0.0 0 0 14 43 12 16 3.4E-02 8.8E-OI 6.7E-01 5.4E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 1 2 7 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 








(cM) Max #Trans to 
2 7 
3 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
2.SOOOOE-02 1.00E-01 O.OOE+OO 8.00E+OO 
2.00E-01 
2 






somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+ol 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 2.0275E-OI 
permutation significance level = l .8400E-O 1 
regression coefficient = 1.8601 E-0 l 
std error of coefficient = 2.2362E-O 1 
regression constant = l. 73l7E-O1 
std error of constant= 4.3303E-02 
t-value for regression coefficient = 8.3 l 83E-O l 
S_est: permutation significance level = 2.8700E-Ol 
anc hap stat: raw, normed = 3.6022E-Ol, -l.2648E-Ol 
replicate samples: mean, std dev = 4.6548E-Ol, 8.3225E-Ol 
S_trim: permutation significance level = l.5800E-Ol 
anc hap stat: raw, normed = 4.23 l lE-Ol, 9.7368E-OI 
replicate samples: mean, std dev = -7.7103E-Ol, l.2264E+OO 
ovlap -#haps- -#peds- ---- prob_() ---
share lh rh t c t c trim c p_t_hs2 
0.5 0 1 3 9 3 8 9.6E-Ol l.9E-Ol 1.4E-OI 3.0E-01 
0.0 0 0 13 55 10 18 4.2E-02 8.IE-01 8.6E-Ol 7.0E-01 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: l 2 8 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 






Allele freqs .15 
(cM) Max #Trans to 
2 8 
4 
( cM) Min Span span affecteds: # Gens 
Disease allele of anc of anc (min) (max) since anc 
position freq loci loci test control mutation alpha 
gamma 
2.SOOOOE-02 l .OOE-0 l O.OOE+OO 8.00E+oO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+Ol 80 80 8.00E+Ol 80 
160 
S_reg: analytical significance oft-value = 5.7559E-OI 
permutation significance level = 5.4800E-O 1 
regression coefficient = -4.1431 E-02 
std error of coefficient= 2. l 735E-O l 
regression constant = l .9048E-O 1 
std error of constant = 4.3808E-02 
t-value for regression coefficient= -1.9062E-O 1 
S_est: permutation significance level = 8.9600E-OI 
anc hap stat: raw, norrned = -8.8819E-02, -7.5212E-O 1 
replicate samples: mean, std dev = 5.0649E-Ol, 7.9152E-Ol 
S_trim: permutation significance level = 4.7800E-OI 
anc hap stat: raw, norrned = -7.9639E-Ol, -52742E-02 
replicate samples: mean, std dev = -7.3167E-01, l.2271E+OO 
ovlap -#haps- -#peds- ---- prob _() ----
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 2 11 2 6 9.6E-OI l.2E-OI l.7E-OI 3.JE-01 
0.0 0 0 14 53 12 18 4.2E-02 8.8E-OI 8.3E-OI 6.7E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 3 9 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 










(cM) Max #Trans to 
Min Span span affecteds: # Gens 
allele ofanc ofanc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
7.SOOOOE-02 l .OOE-01 O.OOE+OO 8.00E+oO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 2.2021E-OI 
permutation significance level = 2.o300E-O 1 
regression coefficient = l .5076E-O 1 
std error of coefficient= ~ .9542E-O 1 
regression constant = 1. 711OE-01 
161 
std error of constant = 4.5041 E-02 
t-value for regression coefficient= 7.7149E-Ol 
S_est: pennutation significance level = 3.8600E-Ol 
anc hap stat: raw, nonned = 3.3449E-Ol, -2.0707E-Ol 
replicate samples: mean, std dev = 52584E-Ol, 9.2408E-01 
S_trim: pennutation significance level = 2.1600E-Ol 
anchapstat: raw, nonned= 5.ll92E-Ol, 9.2205E-OI 
replicate samples: mean, std dev = -5.6690E-Ol, l.l700E+OO 
ovlap -#haps- -#peds- ---- prob _() ---
share lh rh t c t c trim t c p_t_hs2 
0.5 l 0 4 13 4 7 9.6E-OI 2.SE-01 2.0E-01 3.SE-01 
0.0 0 0 12 51 li 17 3.8E-02 7.SE-01 8.0E-01 6.SE-01 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 3 IO 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 









(cM) Max #Trans to 
2 
2 
(cM) Min Span span affecteds: #Gens 
Disease allele ofanc ofanc (min) (max) since anc 
position freq loci loci test control mutation alpha 
gamma 
7.SOOOOE-02 1.00E-01 0.00E+OO 8.00E+OO 
2.00E-01 
2 
Number of replicates (feas/ total) = l 000 / l 000 
Founder haplotypes: 
---pennutation replicates------
200 I .OOE+OO 
-admissible- --locally-admiss-- ----t+c---
somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+ol 80 80 8.00E+Ol 80 
S_reg: analytical significance oft-value = 7.8690E-OI 
pennutation significance level = 7.9800E-Ol 
regression coefficient = -1.4051 E-0 l 
std error of coefficient = l. 7658E-O l 
regression constant = 2.0732E-O l 
std error of constant = 4. 7341 E-02 
t-value for regression coefficient= -7.9571E-01 
S_est: pennutation significance level = 8.5000E-02 
anc hap stat: raw, nonned = l.9202E+o0, l.6824E+OO 
162 
replicate samples: mean, std dev = 5.0575E-Ol, 8.4075E-Ol 
S_trim: permutation significance level = 9.5500E-OI 
anc hap stat: raw, nonned = -l.9728E+o0, -1.5833E+o0 
replicate samples: mean, std dev = -3.5189E-Ol, l.0237E+OO 
ovlap -#haps- -#peds- --- prob _() ---
share lh rh t c t c trim c p_t_hs2 
0.5 l 0 2 21 2 8 9.7E-OI 12E-OI 3.3E-Ol 4.6E-OI 
0.0 0 0 14 43 12 16 3.4E-02 8.8E-01 6.7E-OI 5.4E-Ol 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 3 11 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 








(cM) Max #Trans to 
3 
3 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
1 .50000E-02 l .OOE-01 O.OOE+OO 8.00E+OO 
2.00E-01 
2 
Number ofreplicates (feas/ total)= 10001 1000 
Founder haplotypes: 
---permutation replicates---
200 l .OOE+OO 
-admissible- -locally-admiss-- ---t+c---
somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+ol 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 2.0289E-OI 
permutation significance level = l .8600E-O 1 
regression coefficient = 1.8601E-01 
std error of coefficient = 2.2374E-O l 
regression constant = 1. 73 l 7E-O 1 
std error of constant = 4.3327E-02 
t-value for regression coefficient = 8.3l35E-O1 
S est: permutation significance level = 3.0600E-O 1 
anc hap stat: raw, normed = 3.5990E-Ol, -1.2701E-OI 
replicate samples: mean, std dev = 4.6567E-O I, 8.3282E-O 1 
S_trim: permutation significance level = l.7700E-OI 
anc hap stat: raw, normed = 4.2192E-OI, 9.7248E-OI 
replicate samples: mean, std dev = -7.7140E-OI, l.2271E+OO 
163 
ovlap -#haps- -#peds- --- prob_() ---
share lh rh t c t c trim c p_t_hs2 
0.5 1 0 3 9 3 8 9.6E-OI l.9E-OI l.4E-OI 3.0E-01 
0.0 0 0 13 55 lO 18 4.2E-02 8. IE-01 8.6E-OI 7.0E-01 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 3 12 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 








(cM) Max #Trans to 
4 
4 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position freq loci loci test control mutation alpha 
gamma 
7.SOOOOE-02 1.00E-01 O.OOE+oO 8.00E+OO 2 
2.00E-01 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 5.7556E-OI 
permutation significance level = 5.4900E-O 1 
regression coefficient= -4.1435E-02 
std error of coefficient= 2. l 747E-O 1 
regression constant = l .9049E-O 1 
std error of constant = 4.3832E-02 
t-value for regression coefficient= -1.9054E-O 1 
S_est: permutation significance level = 8.8500E-OI 
anc hap stat: raw, nonned = -8.8507E-02, -7.5163E-OI 
replicate samples: mean, std dev = 5.0675E-OI, 7.9196E-OI 
S_trim: permutation significance level = 4.8900E-OI 
anc hap stat: raw, normed = -7.9758E-OI, -5.3449E-02 
replicate samples: mean, std dev = -7.3196E-OI, l.2277E+OO 
ovlap -#haps- -#peds- ---- prob _() ----
share lh rh t c t c trim t c p_t_hs2 
164 
0.5 1 0 2 Il 2 6 9.6E-OI l.2E-OI l.7E-OI 3.3E-OI 
0.0 0 0 14 53 12 18 4.2E-02 8.8E-OI 8.3E-OI 6.7E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 4 13 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=füced) 






Allele freqs .21 
(cM) Max #Trans to 
2 5 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
7.50000E-02 l.OOE-01 O.OOE+oO 8.00E+OO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+Ol 80 80 8.00E+Ol 80 
S _reg: analytical significance of t-value = l .6052E-O 1 
permutation significance level = l.7300E-OI 
regression coefficient = l .9782E-O 1 
std error of coefficient = l .9936E-O 1 
regression constant = l .6734E-O 1 
std error of constant = 4.4578E-02 
t-value for regression coefficient= 9.9230E-O 1 
S_est: permutation significance level = 5.3100E-01 
anc hap stat: raw, normed = 1.292IE-O1, -4.39l5E-O1 
replicate samples: mean, std dev = 4.771 IE-Ol, 7.9222E-Ol 
S_trim: permutation significance level = 2.1800E-01 
anc hap stat: raw, normed = 6.3041E-02, 5.0733E-Ol 
replicate samples: mean, std dev = -5.2036E-OI, 1.1499E+OO 
ovlap -#haps- -#peds- ---- prob _() ----
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 5 11 5 6 9.6E-Ol 3.IE-01 l.7E-Ol 3.3E-Ol 
0.0 0 0 11 53 10 18 3.9E-02 6.9E-Ol 8.3E-01 6.7E-Ol 
165 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 4 14 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 






Allele freqs .38 
(cM) Max #Trans to 
2 6 
2 
( cM) Min Span span affecteds: # Gens 
Disease allele ofanc ofanc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
7.50000E-02 l.OOE-01 O.OOE+OO 8.00E+OO 
2.00E-01 
2 
Number ofreplicates (feas/ total)= 1000 I 1000 
Founder haplotypes: 
---permutation replicates---
200 l .OOE+OO 
-admissible- ---locally-admiss- --t+c---
somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 8.8996E-OI 
permutation significance level = 8.6900E-O 1 
regression coefficient = -2.0007E-O 1 
std error of coefficient = l .63 l 5E-O 1 
regression constant = 2.2588E-O 1 
std error of constant= 5.0779E-02 
t-value for regression coefficient= -1.2263E+OO 
S_est: permutation significance level = 1.7900E-OI 
anc hap stat: raw, normed = 8.0600E-OI, 4.0491E-OI 
replicate samples: mean, std dev = 4.8314E-O 1, 7.9734E-O1 
S_trim: permutation significance level = 9.1200E-OI 
anc hap stat: raw, normed = -1.2438E+o0, -1.1054E+OO 
replicate samples: mean, std dev = -3.0372E-O 1, 8.5041E-01 
ovlap -#haps- --#peds- ---- prob _0 ---
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 3 28 3 14 9.7E-OI 1.9E-OI 4.4E-OI 5.4E-OI 
0.0 0 0 13 36 II 14 3.0E-02 8.IE-01 5.6E-OI 4.6E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 2 4 15 
Current disease position: 2 




marker loci (X=Disease, "="=fixed) 






Allele freqs .23 
(cM) Max #Transto 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 









somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = l.0737E-OI 
permutation significance level = l .0700E-O 1 
regression coefficient = 2.3609E-O 1 
std error of coefficient = l .9030E-O 1 
regression constant = l .6056E-O 1 
std error of constant= 4.5 l 33E-02 
t-value for regression coefficient = l .2407E +OO 
S_est: permutation significance level = 7.9000E-02 
anc hap stat: raw, normed = l .6338E+OO, l .2633E+OO 
replicate samples: mean, std dev = 4.9906E-OI, 8.9823E-OI 
S_trim: permutation significance level = 4.4000E-02 
anc hap stat: raw, normed = 1.5341 E+OO, l.8426E+OO 
replicate samples: mean, std dev = -5.5082E-O1, l . l 3 l 5E +OO 
ovlap -#haps- -#peds- ---- prob _() -----
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 6 12 6 9 9.6E-OI 3.8E-01 1.9E-OI 3.4E-OI 
0.0 0 0 10 52 9 18 3.7E-02 6.2E-01 8.IE-01 6.6E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 3 5 16 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=tixed) 





Allele freqs 21 
(cM) Max #Trans to 




allele of anc of anc (min) (max) since anc 
freq loci loci test control mutation alpha 
125000E-OI l.OOE-01 O.OOE+oO 8.00E+oO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = l.6052E-OI 
permutation significance level = l.7300E-OI 
regression coefficient = l .9782E-O 1 
std error of coefficient = 1. 9936E-O 1 
regression constant = l .6734E-O 1 
std error of constant= 4.4578E-02 
t-value for regression coefficient= 9.9230E-O 1 
S_est: permutation significance level = 5.3 IOOE-01 
anc hap stat: raw, normed = l.2921E-OI, -4.3915E-01 
replicate samples: mean, std dev = 4.771 IE-OI, 7.9222E-OI 
S_trim: permutation significance level = 2.1800E-OI 
anc hap stat: raw, normed = 6.3041E-02, 5.0733E-OI 
replicate samples: mean, std dev = -5.2036E-OI, 1.1499E+OO 
ovlap -#haps- -#peds- ---- prob _() ---
share th rh t c t c trim t c p_t_hs2 
0.5 1 0 5 11 5 6 9.6E-OI 3.IE-01 l.7E-OI 3.3E-OI 
0.0 0 0 Il 53 10 18 3.9E-02 6.9E-OI 8.3E-OI 6.7E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 3 5 17 
Current disease position: 
Current ancestral !oci: 
marker loci (X=Disease, "="=fixed) 








(cM) Max #Trans to 
2 
2 
(cM) Min Span span affecteds: #Gens 
Disease allele ofanc ofanc (min) (max) since anc 
position freq loci loci test control mutation alpha 
168 
gamma 
125000E-OI l.OOE-01 O.OOE+oO 8.00E+oO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+ol 80 80 8.00E+Ol 80 
S_reg: analytical significance oft-value = 8.8996E-OI 
permutation significance level = 8.6900E-O l 
regression coefficient = -2.0007E-O 1 
std error of coefficient = l .631 SE-O l 
regression constant= 2.2588E-O l 
std error of constant= 5.0779E-02 
t-value for regression coefficient= -l.2263E+OO 
S_est: permutation significance level = l.7900E-OI 
anc hap stat: raw, normed = 8.0600E-OI, 4.0491E-Ol 
replicate samples: mean, std dev = 4.83 l4E-Ol, 7.9734E-OI 
S_trim: permutation significance level = 9.1200E-OI 
anc hap stat: raw, nonned = -l.2438E+o0, -l.l054E+o0 
replicate samples: mean, std dev = -3.0372E-Ol, 8.5041E-OI 
ovlap -#haps- --#peds- --- prob _() ---
share lh rh t c t c trim c p_t_hs2 
0.5 l 0 3 28 3 14 9.7E-Ol l.9E-Ol 4.4E-Ol 5.4E-OI 
0.0 0 0 13 36 11 14 3.0E-02 8.lE-01 5.6E-Ol 4.6E-Ol 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 3 5 18 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 








(cM) Max #Trans to 
3 
3 
( cM) Min Span span affecteds: # Gens 
Disease allele of anc of anc (min) (max) since anc 
position freq loci loci test contrai mutation alpha 
gamma 
l.25000E-O l l.OOE-0 l O.OOE+oO 8.00E+OO 
2.00E-01 
2 
Number ofreplicates (feas/ total)= 1000 / 1000 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+Ol 80 80 8.00E+Ol 80 
S_reg: analytical significance oft-value = l.0737E-Ol 
permutation significance level = l .0700E-O l 
regression coefficient = 2.3609E-O l 
std error of coefficient = l .9030E-O l 
regression constant = l .6056E-O l 
std errorofconstant = 4.5133E-02 
t-value for regression coefficient= 12407E+OO 
S_est: permutation significance level = 7.9000E-02 
anc hap stat: raw, normed = l.6338E+OO, l.2633E+OO 
replicate samples: mean, std dev = 4.9906E-Ol, 8.9823E-Ol 
S_trim: permutation significance level = 4.4000E-02 
anc hap stat: raw, normed = l.5341E+OO, l.8426E+OO 
replicate samples: mean, std dev = -5.5082E-O1, l. l 3 l 5E +OO 
ovlap -#haps- -#peds- ---- prob _() ---
share lh rh t c t c trim c p_t_hs2 
0.5 l 0 6 12 6 9 9.6E-Ol 3.8E-Ol l.9E-Ol 3.4E-Ol 
0.0 0 0 10 52 9 18 3.7E-02 6.2E-OI 8.IE-01 6.6E-Ol 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 3 6 19 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 






Allele freqs .13 





Min Span span atîecteds: # Gens 
gamma 
allele of anc of anc (min) (max) since anc 
freq loci loci test control mutation alpha 
l.25000E-Ol 1.00E-01 O.OOE+OO 8.00E+OO 2 200 l .OOE+OO 
2.00E-01 




80 80 16 
----permutation replicates-----
--locally-admiss-- ---t+c---
test control t+c min mean max min mean 
64 80 80 8.00E+Ol 80 80 8.00E+Ol 80 
max 
170 
S_reg: analytical significance oh-value= 42864E-OI 
permutation significance level = 42700E-O 1 
regression coefficient = 4.3627E-02 
std error of coefficient = 2.4259E-O 1 
regression constant = l .8439E-O 1 
std error of constant= 4.2884E-02 
t-value for regression coefficient = 1. 7984E-O 1 
S_est: permutation significance level = 9.6100E-OI 
anc hap stat: raw, normed = O.OOOOE+oO, -6.l 107E-01 
replicate samples: mean, std dev = 5.3115E-01, 8.6922E-OI 
S_trim: permutation significance level = 5.7200E-OI 
anc hap stat: raw, normed = -1.4634E+o0, -5.1441E-OI 
replicate samples: mean, std dev = -7.6697E-OI, l.3539E+OO 
ovlap -#haps- -#peds- --- prob _() ----
share th rh t c t c trim t c p_t_hs2 
0.5 0 1 2 8 2 4 9.6E-OI 1.2E-OI l.2E-OI 2.9E-OI 
0.0 0 0 14 56 12 18 4.2E-02 8.8E-OI 8.8E-OI 7.IE-01 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 3 6 20 
Current disease position: 2 5 
Current ancestral loci: 2 
marker loci (X=Disease, "="=fixed) 








(cM) Max #Trans to 
Min Span span affecteds: # Gens (cM) 
Disease 
position 
allele of anc of anc (min) (max) since anc 
freq loci loci test control mutation alpha 
gamma 
l.25000E-01 1.00E-01O.OOE+oO8.00E+OO 2 
2.00E-01 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S_reg: analytical significance oft-value = 4.0537E-OI 
permutation significance level = 3.9000E-O 1 
regression coefficient= 4.1011 E-02 
std error of coefficient = 1. 7I26E-O1 
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regression constant = l .8046E-O 1 
std error of constant= 4.88 l 7E-02 
t-value for regression coefficient = 2.3946E-O 1 
S_est: permutation significance level = 3.8000E-Ol 
anc hap stat: raw, normed = 2.4868E-Ol, -2.3926E-Ol 
replicate samples: mean, std dev = 4.3217E-OI, 7.6691E-OI 
S_trim: permutation significance level = 2.0400E-Ol 
anc hap stat: raw, normed = 2.8065E-Ol, 7.3042E-OI 
replicate samples: mean, std dev = -3.7764E-Ol, 9.0125E-Ol 
ovlap -#haps- -#peds- --- prob _() ---
share lh rh t c t c trim t c p_t_hs2 
0.5 0 1 6 20 6 12 9.7E-Ol 3.8E-Ol 3.lE-01 4.4E-Ol 
0.0 0 0 10 44 8 18 3.4E-02 6.2E-Ol 6.9E-Ol 5.6E-OI 
Haplotype-wise analysis: number of feasible configurations for: 
Disease position Ancestral loci Ancestral haps 
Sean to date: 3 6 21 
Current disease position: 
Current ancestral loci: 
marker loci (X=Disease, "="=fixed) 






Allele freqs .22 
(cM) Max #Trans to 
2 6 
3 
(cM) Min Span span affecteds: #Gens 
Disease allele of anc of anc (min) (max) since anc 
position 
gamma 
freq loci loci test control mutation alpha 
l.25000E-01 l.OOE-01 O.OOE+OO 8.00E+OO 
2.00E-01 
2 





somewhere local test control t+c min mean max min mean max 
80 80 16 64 80 80 8.00E+OI 80 80 8.00E+OI 80 
S _reg: analytical significance of t-value = 5.8476E-O1 
permutation significance level = 5.5700E-Ol 
regression coefficient= -4.l 126E-02 
std error of coefficient= 1.9211E-01 
regression constant= l .9l75E-O1 
std error of constant= 4.5562E-02 
t-value for regression coefficient = -2. l 408E-O 1 
S_est: permutation significance level = 4.8700E-OI 
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anc hap stat: raw, normed = l.5238E-OI, -4.1297E-01 
replicate samples: mean, std dev = 4.951OE-01, 8.2989E-O 1 
S_trim: permutation significance level = 7.8200E-Ol 
anc hap stat: raw, normed =-l.1965E+o0, -5.8811E-01 
replicate samples: mean, std dev = -5.3554E-OI, l.1239E+OO 
ovlap -#haps- -#peds- --- prob _() ---
share lh rh t c t c trim c p_t_hs2 
0.5 0 1 2 16 2 10 9.6E-OI l.2E-OI 2.5E-OI 3.9E-OI 
0.0 0 0 14 48 12 17 3.8E-02 8.8E-Ol 7.5E-OI 6.IE-01 
Summary for HAL scan-wise statistics: 
S _reg: permutation significance level = 8.4600E-O 1 
minimum significance oft-value = l.0737E-OI 
S_est: permutation significance level = 6.1900E-OI 
maximum S_est value= l.6824E+OO 
S_trim: permutation significance level = 4.8900E-OI 
maximum S trim value = l .8426E+OO 
Number of replicates (feasible I total) = 1000 I 1000 
# Created on Fri Mar 24 15:21:12 2000 
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Appendix6 
Result file of DISLAMB program 
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••••••••••••• marker 1 (ignore 1 alleles) 
Disease allele frequency = 0.00100000 
CASE 1 2 1 2 1 5 1 5 1 2 1 0 1 2 1 6 1 3 1 
CONTROL 1 71 5 1 15 1 5 1 3 1 4 1 2 1 5 1 5 1 
Estimated parameters for likelihood ratio test: 
Allele frequencies: 
Alle le HO: H 1 
1 0.11538462 0.11538462 
2 0.08974359 0.08974359 
3 0.25641026 0.25641026 
4 0.12820513 0.12820513 
5 0.06410256 0.06410256 
6 0.05128205 0.05128205 
7 0.05128205 0.05128205 
8 0.14102564 0.14102564 
9 0.10256410 0.10256410 
Lambda 0.00000000 0.000000 
LRT Chi-Square= 0.00000 p-value = 0.499999810123862 Lambda= 
0.000000 
NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUILIBRIUM BY LRT TEST 
2 x n table Chi-square= 7.14636 P-value = 0.520926633189796 
NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUILIBRIUM BY 2 x N TABLE CHI-SQUARE 
TEST 
•••• ••••••••• marker 2 (ignore 2 aile les) 
Disease allele frequency = 0.00100000 
CASE 1 01 41 81 41 51 51 
CONTROL I 31 141 161 3 I 71 71 
Estimated parameters for likelihood ratio test: 
Allele frequencies: 
Allele HO: H 1 
1 0.03947368 0.03947368 
2 0.23684211 0.23684211 
3 0.3157894 7 0.3157894 7 
4 0.09210526 0.09210526 
5 0.15789474 0.15789474 
6 0.15789474 0.15789474 
Lambda 0.00000000 0.000000 
LRT Chi-Square = 0.00000 p-value = 0.500000000000000 Lambda= 
0.000000 
NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUILIBRIUM BY LRT TEST 
2 x n table Chi-square= 4.94603 P-value = 0.422523771730510 
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NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUILIBRIUM BY 2 x N TABLE CHI-SQUARE 
TEST 
••••••••••••• marker 3 (ignore 2 alleles) 
CASE I 6 1 10 1 3 1 1 1 7 1 
CONTROL ! 10 I 20 I 2 I 7 I 11 I 
Estimated parameters for likelihood ratio test: 
Allele frequencies: 
Alle le HO: H 1 
1 0.20779221 0.20779221 
2 0.38961039 0.38961039 
3 0.06493506 0.06493507 
4 0.10389610 0.10389611 
5 0.23376623 0.23376623 
Lambda 0.00000000 0.000000 
LRT Chi-Square = 0.00000 p-value = 0.500000000000000 Lambda= 
0.000000 
NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUlLIBRIUM BY LRT TEST 
2 x n table Chi-square= 3.35108 P-value = 0.500879294159147 
NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUlLIBRIUM BY 2 x N TABLE CHI-SQUARE 
TEST 
••••••••••••• marker4 
CASE 1 0 1 2 1 1 1 1 1 4 1 1 1 11 1 5 1 2 1 
CONTROL I 3 I 5 1 2 1 2 1 6 1 6 1 13 1 12 1 3 1 
Estimated parameters for likelihood ratio test: 
Allele frequencies: 
Alle le HO: H 1 
1 0.03797468 0.03797468 
2 0.08860759 0.08860760 
3 0.03797468 0.03797468 
4 0.03797468 0.03797468 
5 0.12658228 0.12658228 
6 0.08860759 0.08860760 
7 0.30379747 0.30379746 
8 0.21518987 0.21518987 
9 0.06329114 0.06329114 
Lambda 0.00000000 0.000000 
LRT Chi-Square = 0.00000 p-value = 0.499999810123862 Lambda= 
0.000000 
NO SIGNIFICANT EVIDENCE OF LINKAGE DISEQUILIBRIUM BY LRT TEST 
2 x n table Chi-square= 4.73569 P-value = 0.785416372092084 
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Result file of GASSOC program 
178 
************************************************* 
* gassoc Version l.05 
************************************************* 
ANAL YSIS FOR MARKER: 2 
Summary lnfo: 
#of valid lines in input file: 83 
#of affected cases: 43 
#of affected cases used in analysis: 25 
# of affected cases not used: 18 
# not used due to missing parent or missing parent alleles: 18 
# not used due to case missing alleles: 0 
# not used due to inconsistent parent/case alleles: 0 
Conditional Logistic: 
Final estimates of Beta: 
Rel. Risk 
Allele Beta exp(Beta) SE(Beta) Z P(2-sided) 
16.2029 10884982.3001 5439.5270 0.0030 0.99762332 
2 0.2750 l.3165 0.6805 0.4040 0.68617994 
3 -l.2268 0.2932 l.1829 -l.0371 0.29968361 
5 -l.0064 0.3655 l.1892 -0.8463 0.39740465 
6 -16.6553 0.0000 2377.2499 -0.0070 0.99440997 
7 -l.4055 0.2452 l.5382 -0.9137 0.36086625 
8 -15.7446 0.0000 3746.0806 -0.0042 0.99664654 
9 l.0986 3.0000 l.1547 0.9514 0.34138810 
10 ***Unable to compute*** 
LR Statistic: 15.3742, df=8, p=0.052265076 
Covariance/Correlation Matrix (*=Corr(Bi.Bj)): 
29588454.3824 0.0000* 0.0000* 0.0000* 
0.0000* 0.0000* 0.0000* 0.0000* NaN* 
0.0000 0.463 l 0.3224* 0.0000* 
0.0000* 0.0000* -0.0000* -0.0000* NaN* 
0.0000 0.2595 l.3992 0.0000* 
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0.0000* 0.0000* -0.0000* 
0.0000 0.0000 0.0000 
0.0003* 0.5817* -0.0000* 







0.0002* -0.0000* -0.0000* 
0.0000 0.0000 0.0000 1.0641 
NaN* 
NaN* 
0.7073 2.3661 -0.0000* -0.0000* NaN* 
0.0000 -0.0000 -0.0000 -0.0000 
-0.0000 -0.0000 14033120.1943 0.0001* NaN* 
0.0000 -0.0000 -0.0000 -0.0000 
-0.0000 -0.0000 0.3333 l.3333 NaN* 
0.0000 -0.0000 -0.0000 -0.0000 
-0.0000 -0.0000 0.0000 0.0000 0.0000 
Score Statistics: 
Score df P-value Sim P-value(Simulations=2) 
GTDT: 11.7064 8 0.164793530 0.000000000 
GDOM: 12.5603 9 0.183530602 0.000000000 
GREC: 8.5789 6 0.198678847 0.500000000 
Note: Seeds used for random# generation were 942, 18223, 8374 
ANAL YSIS FOR MARKER: 3 
Summary lnfo: 
#of valid lines in input file: 83 
#of affected cases: 43 
#of affected cases used in analysis: 25 
#of affected cases not used: 18 
# not used due to missing parent or missing parent alleles: 18 
# not used due to case missing alleles: 0 
# not used due to inconsistent parent/case alleles: 0 
Conditional Logistic: 
Final estimates of Beta: 
Rel. Risk 
180 
Allele Beta exp(Beta) SE(Beta) Z P(2-sided) 
15.2029 4004360.2052 2332.9149 0.0065 0.99480047 
2 1.5569 4.7440 1.1581 1.3443 0.17884762 
4 -0.6270 0.5342 1.2510 -0.5012 0.61622551 
5 -16.3895 0.0000 3299.2405 -0.0050 0.99603639 
6 0.0661 1.0684 1.7507 0.0378 0.96986349 
7 -1.1866 0.3053 1.9256 -0.6162 0.53773424 
8 -15.8773 0.0000 2252.2533 -0.0070 0.99437534 
LR Statistic: 14.4397, df=7. p=0.043891853 
Covariance/Correlation Matrix (*=Corr(Bi,Bj)): 
5442492.1500 0.0000* 0.0000* 0.0000* 
0.0000* 0.0000* 0.0000* 
0.0000 1.3413 0.3476* 0.0001* 
0.2484* 0.2258* 0.0002* 
0.0000 0.5036 1.5650 0.0004* 
0.7146* 0.6497* 0.0006* 
0.0000 0.5036 1.5650 10884988.0060 
0.0005* 0.0006* 0.0000* 
0.0000 0.5036 1.5650 3.0650 
3.0650 0.9092* 0.0008* 
0.0000 0.5036 1.5650 3.7078 
3.0650 3.7078 0.0008* 
0.0000 0.5036 1.5650 3.5650 
3.0650 3.5650 5072644.8277 
Score Statistics: 
Score df P-value Sim P-value(Simulations=2) 
GTDT: 11.7341 7 0.109647704 0.000000000 
GOOM: 10.8301 7 0.146202442 0.000000000 
GREC: 7.6061 5 0.179324534 0.000000000 
Note: Seeds used for random# generation were 942, 18223, 8374 
ANAL YSIS FOR MARKER: 4 
Summary lnfo: 
#of valid lines in input file: 83 
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#of affected cases: 43 
#of affected cases used in analysis: 25 
# of affected cases not used: 18 
# not used due to missing parent or missing parent alleles: 18 
# not used due to case missing alleles: 0 
# not used due to inconsistent parent/case alleles: 0 
Conditional Logistic: 















-14.0902 0.0000 1904.8172 -0.0074 0.99409799 
15.2029 4004360.2052 3299.2400 0.0046 0.99632336 
0.0000 l.0000 0.8165 0.0000 l.00000000 
1.1127 3.0426 0.7672 l.4503 0.14697893 
LR Statistic: 10.9601, df=6, p=0.089616297 
Covariance/Correlation Matrix (*=Corr(Bi.Bj)): 

















0.0000 l 0884984.3000 
-0.0000 -0 .0000 -0.0000 -0.0000 
0.6667 -0.0000* 
0.0000 0.3289 0.5886 0.0000 
-0.0000 0.5886 
Score Statistics: 
Score df P-value Sim P-value(Simulations=2) 
GTDT: 8.8168 6 0.184146637 0.500000000 
GDOM: 7.7796 6 0.254700460 0.000000000 
GREC: 4.9259 4 0.294988290 0.500000000 
Note: Seeds used for random# generation were 942, 18223, 8374 
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ANAL YSIS FOR MARKER: 5 
Summary lnfo: 
#of valid lines in input file: 83 
# of affected cases: 43 
#of affected cases used in analysis: 25 
#of affected cases not used: 18 
# not used due to missing parent or missing parent alleles: 18 
# not used due to case missing alleles: 0 
# not used due to inconsistent parent/case alleles: 0 
Conditional Logistic: 
Final estimates of Beta: 
Rel. Risk 
Allele Beta exp(Beta) SE(Beta) z P(2-sided) 
l 0.4960 l.6421 l.7037 0.2911 0.77095833 
2 15.4266 5008405.0965 1649.3944 0.0094 0.99253757 
3 0.0000 1.0000 l.0000 0.0000 1.00000000 
4 -15.2029 0.0000 2332.9149 -0.0065 0.99480047 
5 0.4960 l.6421 0.9500 0.5221 0.60161178 
6 0.1850 1.2032 0.9127 0.2027 0.83935270 
8 0.2615 1.2989 0.6413 0.4078 0.68341738 
9 0.0925 1.0969 1.4875 0.0622 0.95040920 
LR Statistic: 8.6941. df=8. p=0.368750702 
Covariance/Correlation Matrix (*=Corr(Bi,Bj)): 
2.9025 0.0001 * 0.0000* 0.0000* 
0.5576* 0.1321 * 0.1097* 0.0405* 
0.1610 2720501.9341 0.0000* 0.0000* 
0.0001* 0.0003* 0.0003* 0.0001* 
0.0000 0.0000 1.0000 -0.0000* 
0.0000* 0.0000* 0.0000* 0.0000* 





0.9025 0.2369* 0.1967* 
0.2054 0.4899 0.0000 







0.1199 0.2962 0.0000 0.0000 
0.1199 0.1720 0.4113 0.0902* 
0.1027 0.2449 0.0000 0.0000 
0.1027 0.4165 0.0860 2.2125 
Score Statistics: 
Score df P-value Sim P-value(Simulations=2) 
GTDT: 6.3729 8 0.605542445 0.500000000 
GDOM: 6.3844 8 0.604251878 l.000000000 
GREC: 5.9220 5 0.313884220 0.000000000 
Note: Seeds used for random# generation were 942, 18223, 8374 
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